|
|
| Zeile 1: |
Zeile 1: |
| | | | |
| | cont as [[TempP(2)]] | | cont as [[TempP(2)]] |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32815099|t=2020. Repurposing calcium channel blockers as antiviral drugs.|pdf=|usr=018}}
| |
| − | {{tp|p=32786695|t=2020. Systemic In Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server.|pdf=|usr=018}}
| |
| − | {{tp|p=32837097|t=2020. Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far.|pdf=|usr=018}}
| |
| − | {{tp|p=32809969|t=2020. Baricitinib restrains the immune dysregulation in severe COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32751615|t=2020. A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing Approach during and after the Coronavirus Disease 2019 Era.|pdf=|usr=018}}
| |
| − | {{tp|p=32727069|t=2020. A Cell-Based Reporter Assay for Screening Inhibitors of MERS Coronavirus RNA-Dependent RNA Polymerase Activity.|pdf=|usr=018}}
| |
| − | {{tp|p=32726951|t=2020. Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32872629|t=2020. Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32858940|t=2020. Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients?|pdf=|usr=018}}
| |
| − | {{tp|p=32785135|t=2020. Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy.|pdf=|usr=018}}
| |
| − | {{tp|p=32785121|t=2020. Key Aspects in Nutritional Management of COVID-19 Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32849949|t=2020. Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32849936|t=2020. Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32849934|t=2020. Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review.|pdf=|usr=018}}
| |
| − | {{tp|p=32779201|t=2020. Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations.|pdf=|usr=018}}
| |
| − | {{tp|p=32741525|t=2020. Attenuating hyperinflammation in COVID-19: A change in paradigm?|pdf=|usr=018}}
| |
| − | {{tp|p=32871418|t=2020. Intratracheal administration of autologus conditioned serum for COVID-19 associated respiratory distress syndrome.|pdf=|usr=018}}
| |
| − | {{tp|p=32814271|t=2020. Inhaled nitric oxide in mechanically ventilated patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32827987|t=2020. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32885340|t=2020. The immune-modulatory effects of exercise should be favorably harnessed against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32772324|t=2020. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32860209|t=2020. What we have to know about corticosteroids use during Sars-Cov-2 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=31724441|t=2020. Inhibition of SARS-CoV 3CL protease by flavonoids.|pdf=|usr=018}}
| |
| − | {{tp|p=32678432|t=2020. Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32754467|t=2020. COVID-19: Older drugs for a novel disease-Chloroquine, hydroxychloroquine, and possible Pentoxifylline-set to start the second innings?|pdf=|usr=018}}
| |
| − | {{tp|p=32783247|t=2020. Tannins inhibit SARS-CoV-2 through binding with catalytic dyad residues of 3CL(pro) : An in silico approach with 19 structural different hydrolysable tannins.|pdf=|usr=018}}
| |
| − | {{tp|p=32773258|t=2020. Therapeutic plasma exchange resolving COVID-19 related ARDS.|pdf=|usr=018}}
| |
| − | {{tp|p=32834835|t=2020. Phytochemicals containing biologically active polyphenols as an effective agent against Covid-19-inducing coronavirus.|pdf=|usr=018}}
| |
| − | {{tp|p=32837538|t=2020. Potential compound from herbal food of rhizoma polygonati for treatment of COVID-19 analyzed by network pharmacology and molecular docking technology.|pdf=|usr=018}}
| |
| − | {{tp|p=32885373|t=2020. Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32692647|t=2020. A novel antiviral formulation inhibits a range of enveloped viruses.|pdf=|usr=018}}
| |
| − | {{tp|p=32725286|t=2020. Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32777441|t=2020. Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?|pdf=|usr=018}}
| |
| − | {{tp|p=32763357|t=2020. Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study.|pdf=|usr=018}}
| |
| − | {{tp|p=32828896|t=2020. A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Reunion Island.|pdf=|usr=018}}
| |
| − | {{tp|p=32792611|t=2020. Vitamin D deficiency in African Americans is associated with a high risk of severe disease and mortality by SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32828791|t=2020. Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays.|pdf=|usr=018}}
| |
| − | {{tp|p=32784217|t=2020. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.|pdf=|usr=018}}
| |
| − | {{tp|p=32795481|t=2020. Impact of Routine Infant BCG Vaccination on COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32794463|t=2020. A practical approach for the compassionate use of convalescent plasma in patients with severe COVID-19 in developing countries.|pdf=|usr=018}}
| |
| − | {{tp|p=32726430|t=2020. Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2.|pdf=|usr=018}}
| |
| − | {{tp|p=32798222|t=2020. Plasma from recovered COVID-19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay.|pdf=|usr=018}}
| |
| − | {{tp|p=32779705|t=2020. SARS-CoV-2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in COVID-19 Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32777038|t=2020. Convalescent Plasma Therapy on Patients with Severe or Life-Threatening COVID-19: A Metadata Analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32773212|t=2020. Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review.|pdf=|usr=018}}
| |
| − | {{tp|p=32745348|t=2020. Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32744399|t=2020. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study.|pdf=|usr=018}}
| |
| − | {{tp|p=32837113|t=2020. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme.|pdf=|usr=018}}
| |
| − | {{tp|p=32784192|t=2020. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.|pdf=|usr=018}}
| |
| − | {{tp|p=32767684|t=2020. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.|pdf=|usr=018}}
| |
| − | {{tp|p=32749708|t=2020. Can aldosterone increase interleukin-6 levels in Covid-19 pneumonia?|pdf=|usr=018}}
| |
| − | {{tp|p=32749702|t=2020. Targeting human TLRs to combat COVID-19: A solution?|pdf=|usr=018}}
| |
| − | {{tp|p=32856721|t=2020. Tocilizumab - A beacon of hope in the management of severe COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32841451|t=2020. Targeting NLRP3 Inflammasome in an Animal Model for SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32833258|t=2020. Live unattenuated vaccines for controlling viral diseases including COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32827313|t=2020. Convergence between global BCG vaccination and COVID-19 pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32813283|t=2020. Effectiveness of remdesivir for the treatment of hospitalized Covid-19 persons: a network meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32808712|t=2020. Hydroxychloroquine for treatment of non-severe COVID-19 patients; systematic review and meta-analysis of controlled clinical trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32790075|t=2020. Late onset infectious complications and safety of tocilizumab in the management of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32786041|t=2020. Evaluation of retinotoxicity of COVID-19 treatment: hydroxychloroquine and lopinavir/ritonavir.|pdf=|usr=018}}
| |
| − | {{tp|p=32776573|t=2020. Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32776550|t=2020. Clinical trials of inhaled beclomethasone and mometasone for COVID-19 should be conducted.|pdf=|usr=018}}
| |
| − | {{tp|p=32776534|t=2020. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study.|pdf=|usr=018}}
| |
| − | {{tp|p=32862236|t=2020. Entry Inhibitors: Efficient Means to Block Viral Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32833058|t=2020. Various Facets of Pathogenic Lipids in Infectious Diseases: Exploring Virulent Lipid-Host Interactome and Their Druggability.|pdf=|usr=018}}
| |
| − | {{tp|p=32627758|t=2020. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.|pdf=|usr=018}}
| |
| − | {{tp|p=32855060|t=2020. Potentially fatal severe brady arrythmias related to Lopinavir-Ritonavir in a COVID 19 patient.|pdf=|usr=018}}
| |
| − | {{tp|p=32829149|t=2020. Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2.|pdf=|usr=018}}
| |
| − | {{tp|p=32745925|t=2020. Polyacylated anthocyanins constructively network with catalytic dyad residues of 3CL(pro) of 2019-nCoV than monomeric anthocyanins: A structural-relationship activity study with 10 anthocyanins using in-silico approaches.|pdf=|usr=018}}
| |
| − | {{tp|p=32739642|t=2020. Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment.|pdf=|usr=018}}
| |
| − | {{tp|p=32866780|t=2020. Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32861974|t=2020. Molecular modelling investigation for drugs and nutraceuticals against protease of SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32863490|t=2020. Structural and physico-chemical evaluation of melatonin and its solution-state excited properties, with emphasis on its binding with novel coronavirus proteins.|pdf=|usr=018}}
| |
| − | {{tp|p=32839634|t=2020. Investigating the potential antiviral activity drugs against SARS-CoV-2 by molecular docking simulation.|pdf=|usr=018}}
| |
| − | {{tp|p=32834115|t=2021. Chemical-informatics approach to COVID-19 drug discovery: Exploration of important fragments and data mining based prediction of some hits from natural origins as main protease (Mpro) inhibitors.|pdf=|usr=018}}
| |
| − | {{tp|p=32863430|t=2021. Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors.|pdf=|usr=018}}
| |
| − | {{tp|p=32834114|t=2020. Crystal structure, chemical reactivity, kinetic and thermodynamic studies of new ligand derived from 4-hydroxycoumarin: Interaction with SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32808988|t=2020. Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute COVID-19 in Pediatric Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32764275|t=2020. Postulated Adjuvant Therapeutic Strategies for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32874702|t=2020. Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches.|pdf=|usr=018}}
| |
| − | {{tp|p=32735768|t=2020. Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32829256|t=2020. Laser irradiated phenothiazines: New potential treatment for COVID-19 explored by molecular docking.|pdf=|usr=018}}
| |
| − | {{tp|p=32855026|t=2020. Light-based technologies for management of COVID-19 pandemic crisis.|pdf=|usr=018}}
| |
| − | {{tp|p=32790379|t=2020. Interdiction of Protein Folding for Therapeutic Drug Development in SARS CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32787337|t=2020. Repurposing Low-Molecular-Weight Drugs against the Main Protease of Severe Acute Respiratory Syndrome Coronavirus 2.|pdf=|usr=018}}
| |
| − | {{tp|p=32787328|t=2020. Screening of Therapeutic Agents for COVID-19 Using Machine Learning and Ensemble Docking Studies.|pdf=|usr=018}}
| |
| − | {{tp|p=32770854|t=2020. Clinical trial to test the efficacy of melatonin in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32765615|t=2020. Glucocorticoids in COVID19; a friend not foe.|pdf=|usr=018}}
| |
| − | {{tp|p=32871238|t=2020. "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study".|pdf=|usr=018}}
| |
| − | {{tp|p=32735992|t=2020. Design of an engineered ACE2 as a novel therapeutics against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32839756|t=2020. Azithromycin: The First Broad-spectrum Therapeutic.|pdf=|usr=018}}
| |
| − | {{tp|p=32847594|t=2020. The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=31703698|t=2019. Epitope-based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: an immune-informatics study.|pdf=|usr=018}}
| |
| − | {{tp|p=32441826|t=2020. Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis.|pdf=|usr=018}}
| |
| − | {{tp|p=31462558|t=2019. Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity.|pdf=|usr=018}}
| |
| − | {{tp|p=31578288|t=2019. Small-Molecule Antiviral beta-d-N (4)-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance.|pdf=|usr=018}}
| |
| − | {{tp|p=32748578|t=2020. Interferon-alpha2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study.|pdf=|usr=018}}
| |
| − | {{tp|p=32880651|t=2020. Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results.|pdf=|usr=018}}
| |
| − | {{tp|p=32658285|t=2020. Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32789513|t=2020. Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32776022|t=2020. Structural Basis for Designing Multiepitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation.|pdf=|usr=018}}
| |
| − | {{tp|p=32833241|t=2020. Lessons Learned in Nutrition Therapy in Patients With Severe COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32799322|t=2020. Challenges of Maintaining Optimal Nutrition Status in COVID-19 Patients in Intensive Care Settings.|pdf=|usr=018}}
| |
| − | {{tp|p=32838087|t=2020. Acute kidney injury associated with lopinavir/ritonavir combined therapy in patients with Covid-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32869007|t=2020. Lopinavir-ritonavir associated acute kidney injury is not related to crystalluria in critically-ill COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32729620|t=2020. Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside.|pdf=|usr=018}}
| |
| − | {{tp|p=32798489|t=2020. COVID-19 combination prevention requires attention to structural drivers.|pdf=|usr=018}}
| |
| − | {{tp|p=32798481|t=2020. COVID-19 trial co-enrolment and subsequent enrolment.|pdf=|usr=018}}
| |
| − | {{tp|p=32758429|t=2020. Vitamin D for COVID-19: a case to answer?|pdf=|usr=018}}
| |
| − | {{tp|p=32828171|t=2020. Clinical trials of disease stages in COVID 19: complicated and often misinterpreted.|pdf=|usr=018}}
| |
| − | {{tp|p=32835325|t=2020. Increasing accessibility in COVID-19 clinical trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32723801|t=2020. Drug Discovery Strategies for SARS-CoV-2.|pdf=|usr=018}}
| |
| − |
| |
| − | {{tp|p=32835332|t=2020. Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma.|pdf=|usr=018}}
| |
| − | {{tp|p=32738928|t=2020. Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32835653|t=2020. Apples and oranges: international comparisons of COVID-19 observational studies in ICUs.|pdf=|usr=018}}
| |
| − | {{tp|p=32838317|t=2020. Effect of anakinra in COVID-19 - Authors' reply.|pdf=|usr=018}}
| |
| − | {{tp|p=32838316|t=2020. Effect of anakinra in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32838323|t=2020. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.|pdf=|usr=018}}
| |
| − | {{tp|p=32838322|t=2020. The conundrum of interleukin-6 blockade in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32838321|t=2020. Anakinra for severe forms of COVID-19 - Authors' reply.|pdf=|usr=018}}
| |
| − | {{tp|p=32838320|t=2020. Anakinra for severe forms of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32838319|t=2020. Anakinra for severe forms of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32838318|t=2020. Anakinra for severe forms of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32864627|t=2020. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study.|pdf=|usr=018}}
| |
| − | {{tp|p=32838327|t=2020. Tocilizumab for severe COVID-19 pneumonia.|pdf=|usr=018}}
| |
| − | {{tp|p=32838326|t=2020. Tocilizumab for severe COVID-19 pneumonia - Authors' reply.|pdf=|usr=018}}
| |
| − | {{tp|p=32838325|t=2020. Tocilizumab for severe COVID-19 pneumonia.|pdf=|usr=018}}
| |
| − | {{tp|p=32838324|t=2020. Tocilizumab for severe COVID-19 pneumonia.|pdf=|usr=018}}
| |
| − | {{tp|p=32835256|t=2020. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study.|pdf=|usr=018}}
| |
| − | {{tp|p=32879427|t=2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32814839|t=2020. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.|pdf=|usr=018}}
| |
| − | {{tp|p=32784922|t=2020. A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review.|pdf=|usr=018}}
| |
| − | {{tp|p=32777300|t=2020. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.|pdf=|usr=018}}
| |
| − | {{tp|p=32750438|t=2020. The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32738360|t=2020. Computational guided drug repurposing for targeting 2'-O-ribose methyltransferase of SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32846167|t=2020. Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32841659|t=2020. GRP78 targeting: Hitting two birds with a stone.|pdf=|usr=018}}
| |
| − | {{tp|p=32818545|t=2020. Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges.|pdf=|usr=018}}
| |
| − | {{tp|p=32788852|t=2020. Anti-inflammatory Properties of Stingless Bee Honey May Reduce the Severity of Pulmonary Manifestations in COVID-19 Infections.|pdf=|usr=018}}
| |
| − | {{tp|p=32863755|t=2020. Ivermectin: Potential Role as Repurposed Drug for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32837243|t=2020. Cellular decoys distract coronavirus.|pdf=|usr=018}}
| |
| − | {{tp|p=32829981|t=2020. Be well: A potential role for vitamin B in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32861345|t=2020. Migratory Pulmonary Infiltrates in a Patient With COVID-19 Infection and the Role of Corticosteroids.|pdf=|usr=018}}
| |
| − | {{tp|p=32861340|t=2020. Targeting TMPRSS2 in SARS-CoV-2 Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32861333|t=2020. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32838206|t=2020. A narrative review of emerging therapeutics for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32820005|t=2020. GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32838354|t=2020. What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32838355|t=2020. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32838361|t=2020. Investigating Ketone Bodies as Immunometabolic Countermeasures against Respiratory Viral Infections.|pdf=|usr=018}}
| |
| − | {{tp|p=32837137|t=2020. Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery.|pdf=|usr=018}}
| |
| − | {{tp|p=32838988|t=2020. Indicacion de los pulsos de glucocorticoides en pacientes con infeccion por SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32873396|t=2020. Neumomediastino espontaneo en neumonitis por coronavirus evolucionada.|pdf=|usr=018}}
| |
| − | {{tp|p=32778429|t=2020. Utilizacion de antisepticos orales para la infeccion por SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32838043|t=2020. Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32835213|t=2020. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32763662|t=2020. A putative role for the tobacco mosaic virus in smokers' resistance to COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32763660|t=2020. Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.|pdf=|usr=018}}
| |
| − | {{tp|p=32759016|t=2020. Estrogen shields women from COVID-19 complications by reducing ER stress.|pdf=|usr=018}}
| |
| − | {{tp|p=32768893|t=2020. The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32759013|t=2020. High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumonia.|pdf=|usr=018}}
| |
| − | {{tp|p=32758904|t=2020. N-acetycysteine: A potential therapeutic agent in COVID-19 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32759008|t=2020. Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32759007|t=2020. Prostaglandin D2 as a mediator of lymphopenia and a therapeutic target in COVID-19 disease.|pdf=|usr=018}}
| |
| − | {{tp|p=32758903|t=2020. Mevalonate pathway, selenoproteins, redox balance, immune system, Covid-19: Reasoning about connections.|pdf=|usr=018}}
| |
| − | {{tp|p=32758901|t=2020. Acute respiratory distress syndrome from Covid-19: A perfect storm from free radicals? Proposal for a new treatment.|pdf=|usr=018}}
| |
| − | {{tp|p=32721808|t=2020. Prior infection with intestinal coronaviruses moderates symptom severity and mortality in patients with COVID-19: A hypothesis and preliminary evidence.|pdf=|usr=018}}
| |
| − | {{tp|p=32721806|t=2020. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).|pdf=|usr=018}}
| |
| − | {{tp|p=32758899|t=2020. BCG vaccination and COVID-19: Much ado about nothing?|pdf=|usr=018}}
| |
| − | {{tp|p=32721805|t=2020. Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin.|pdf=|usr=018}}
| |
| − | {{tp|p=32795835|t=2020. Is there a role for insulin-like growth factor inhibition in the treatment of COVID-19-related adult respiratory distress syndrome?|pdf=|usr=018}}
| |
| − | {{tp|p=32795832|t=2020. Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32852058|t=2020. The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.|pdf=|usr=018}}
| |
| − | {{tp|p=32838397|t=2020. Regulatory T cells: A potential weapon to combat COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32658856|t=2020. Efectos adversos cardiacos de hidroxicloroquina y la necesidad de ensayos.|pdf=|usr=018}}
| |
| − | {{tp|p=32658855|t=2020. Seguridad cardiovascular de la hidroxicloroquina en la pandemia de COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32658853|t=2020. Uso de plasma de convalecientes para tratamiento de COVID-19. Historia y evidencia.|pdf=|usr=018}}
| |
| − | {{tp|p=32658841|t=2020. Desarrollo de un suero equino hiperinmune para el tratamiento de COVID-19 en Argentina.|pdf=|usr=018}}
| |
| − | {{tp|p=32752010|t=2020. Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An Algorithm for Its Application.|pdf=|usr=018}}
| |
| − | {{tp|p=32727107|t=2020. Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.|pdf=|usr=018}}
| |
| − | {{tp|p=32825011|t=2020. Can Bioactive Lipid Arachidonic Acid Prevent and Ameliorate COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32756215|t=2020. Therapeutic response to corticosteroids in a critically ill patient with COVID-19: A case report.|pdf=|usr=018}}
| |
| − | {{tp|p=32756149|t=2020. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report.|pdf=|usr=018}}
| |
| − | {{tp|p=32791753|t=2020. A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019.|pdf=|usr=018}}
| |
| − | {{tp|p=32791699|t=2020. The effectiveness and safety of traditional Chinese medicine for the treatment of children with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32769922|t=2020. A systematic review and meta-analysis of the efficacy and safety of western medicine routine treatment combined with Chinese herbal medicine in the treatment of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32846825|t=2020. Epidemiological and clinical features of 201 COVID-19 patients in Changsha city, Hunan, China.|pdf=|usr=018}}
| |
| − | {{tp|p=32808940|t=2020. The therapeutic potential of colchicine in the complications of COVID19. Could the immunometabolic properties of an old and cheap drug help?|pdf=|usr=018}}
| |
| − | {{tp|p=32162250|t=2020. A Computational Vaccine Designing Approach for MERS-CoV Infections.|pdf=|usr=018}}
| |
| − | {{tp|p=32835775|t=2020. Identification B and T-Cell epitopes and functional exposed amino acids of S protein as a potential vaccine candidate against SARS-CoV-2/COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32818576|t=2020. The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?|pdf=|usr=018}}
| |
| − | {{tp|p=32878286|t=2020. Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids.|pdf=|usr=018}}
| |
| − | {{tp|p=32825283|t=2020. Novel Antiviral Strategies in the Treatment of COVID-19: A Review.|pdf=|usr=018}}
| |
| − | {{tp|p=32824639|t=2020. Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease.|pdf=|usr=018}}
| |
| − | {{tp|p=32853546|t=2020. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.|pdf=|usr=018}}
| |
| − | {{tp|p=32877642|t=2020. Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication.|pdf=|usr=018}}
| |
| − | {{tp|p=32880078|t=2020. Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to.|pdf=|usr=018}}
| |
| − | {{tp|p=32737681|t=2020. Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach.|pdf=|usr=018}}
| |
| − | {{tp|p=32750187|t=2020. Insights on 3D Structures of Potential Drug-Targeting Proteins of SARS-CoV-2: Application of Cavity Search and Molecular Docking.|pdf=|usr=018}}
| |
| − | {{tp|p=32808122|t=2020. Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32729248|t=2020. In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression.|pdf=|usr=018}}
| |
| − | {{tp|p=32882868|t=2020. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32784680|t=2020. Anticancer and Antiviral Properties of Cardiac Glycosides: A Review to Explore the Mechanism of Actions.|pdf=|usr=018}}
| |
| − | {{tp|p=32872217|t=2020. Biochemical and Computational Approach of Selected Phytocompounds from Tinospora crispa in the Management of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32867349|t=2020. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.|pdf=|usr=018}}
| |
| − | {{tp|p=32842509|t=2020. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method.|pdf=|usr=018}}
| |
| − | {{tp|p=32842606|t=2020. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32824454|t=2020. Putative SARS-CoV-2 M(pro) Inhibitors from an In-House Library of Natural and Nature-Inspired Products: A Virtual Screening and Molecular Docking Study.|pdf=|usr=018}}
| |
| − | {{tp|p=32836400|t=2020. Alte Medikamente in neuen Schuhen. Substanzen, die gegen COVID-19 (nicht) zum Einsatz kommen.|pdf=|usr=018}}
| |
| − | {{tp|p=32763844|t=2020. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32722908|t=2020. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.|pdf=|usr=018}}
| |
| − | {{tp|p=32825737|t=2020. Antiviral Potential of Nanoparticles-Can Nanoparticles Fight Against Coronaviruses?|pdf=|usr=018}}
| |
| − | {{tp|p=32873192|t=2020. No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32857226|t=2020. Nano-clays as Potential Pseudo-antibodies for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32855401|t=2020. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.|pdf=|usr=018}}
| |
| − | {{tp|p=32848158|t=2020. Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32843628|t=2020. A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32826924|t=2020. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques.|pdf=|usr=018}}
| |
| − | {{tp|p=32826914|t=2020. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.|pdf=|usr=018}}
| |
| − | {{tp|p=32796842|t=2020. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge.|pdf=|usr=018}}
| |
| − | {{tp|p=32792628|t=2020. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.|pdf=|usr=018}}
| |
| − | {{tp|p=32772313|t=2020. Anthraquinone Derivatives as an Immune Booster and their Therapeutic Option Against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32873977|t=2020. The COVID-19 pandemic: a catalyst to improve clinical trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32873887|t=2020. Inhaled nanobodies against COVID-19.|pdf=|usr=018}}
| |
| − |
| |
| − | {{tp|p=32807860|t=2020. A cocktail of antibodies for COVID-19 therapy.|pdf=|usr=018}}
| |
| − | {{tp|p=32782354|t=2020. SARS-CoV-2 vaccine - think globally, act locally.|pdf=|usr=018}}
| |
| − | {{tp|p=32778829|t=2020. After 62 years of regulating immunity, dexamethasone meets COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32776624|t=2020. Clinical benefits of Tocilizumab in COVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia.|pdf=|usr=018}}
| |
| − | {{tp|p=32834922|t=2020. Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease.|pdf=|usr=018}}
| |
| − | {{tp|p=32839670|t=2020. Hydroxychloroquine is protective to the heart, not harmful: a systematic review.|pdf=|usr=018}}
| |
| − | {{tp|p=32864162|t=2020. Pharmacogenomics of COVID-19 therapies.|pdf=|usr=018}}
| |
| − | {{tp|p=32793398|t=2020. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32872374|t=2020. Antiviral Functional Foods and Exercise Lifestyle Prevention of Coronavirus.|pdf=|usr=018}}
| |
| − | {{tp|p=32854262|t=2020. The Antiviral, Anti-Inflammatory Effects of Natural Medicinal Herbs and Mushrooms and SARS-CoV-2 Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32847033|t=2020. Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed.|pdf=|usr=018}}
| |
| − | {{tp|p=32842513|t=2020. Could Vitamins Help in the Fight Against COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32844132|t=2020. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32817375|t=2020. Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?|pdf=|usr=018}}
| |
| − | {{tp|p=32837535|t=2020. What is the best mouthrinse against Coronaviruses?|pdf=|usr=018}}
| |
| − | {{tp|p=32667665|t=2020. Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19).|pdf=|usr=018}}
| |
| − | {{tp|p=32751194|t=2020. Newcastle Disease Virus as a Vaccine Vector for SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32832263|t=2020. Anti-COVID-19 multi-epitope vaccine designs employing global viral genome sequences.|pdf=|usr=018}}
| |
| − | {{tp|p=32889022|t=2020. Peptides to combat viral infectious diseases.|pdf=|usr=018}}
| |
| − | {{tp|p=32778962|t=2020. Repurposing of Kinase Inhibitors for Treatment of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32882888|t=2020. Zinc(II)-The Overlooked Eminence Grise of Chloroquine's Fight against COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32784499|t=2020. Emerging Therapeutic Modalities against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32397649|t=2020. MERS-CoV Spike Protein Vaccine and Inactivated Influenza Vaccine Formulated with Single Strand RNA Adjuvant Induce T-Cell Activation through Intranasal Immunization in Mice.|pdf=|usr=018}}
| |
| − | {{tp|p=32880878|t=2020. How Should a Safe and Effective COVID-19 Vaccine be Allocated? Health Economists Need to be Ready to Take the Baton.|pdf=|usr=018}}
| |
| − | {{tp|p=32816200|t=2020. Pharmacological treatments of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32781283|t=2020. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial.|pdf=|usr=018}}
| |
| − | {{tp|p=32866599|t=2020. Chinese herbal medicine supplementation therapy on COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32791263|t=2020. Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study.|pdf=|usr=018}}
| |
| − | {{tp|p=32715661|t=2020. Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32763473|t=2020. Ultraviolet germicidal irradiation for filtering facepiece respirators disinfection to facilitate reuse during COVID-19 pandemic: A review.|pdf=|usr=018}}
| |
| − | {{tp|p=32818638|t=2020. Photodynamic and Sonodynamic Therapy of Acute Hypoxemic Respiratory Failure in Patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32776317|t=2020. Low dose radiation therapy for COVID-19 pneumonia: brief review of the evidence.|pdf=|usr=018}}
| |
| − | {{tp|p=32809918|t=2020. Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.|pdf=|usr=018}}
| |
| − | {{tp|p=32639219|t=2020. Anti-protease Treatments Targeting Plasmin(ogen) and Neutrophil Elastase May Be Beneficial in Fighting COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32639181|t=2020. Consideration of Tranexamic Acid Administration to COVID-19 Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32741697|t=2020. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review.|pdf=|usr=018}}
| |
| − | {{tp|p=32798019|t=2020. Therapeutic options of TCM for organ injuries associated with COVID-19 and the underlying mechanism.|pdf=|usr=018}}
| |
| − | {{tp|p=32843234|t=2020. Prevention and treatment of COVID-19 using Traditional Chinese Medicine: A review.|pdf=|usr=018}}
| |
| − | {{tp|p=32890913|t=2020. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-kappaB) signaling pathway.|pdf=|usr=018}}
| |
| − | {{tp|p=32779813|t=2020. Rugosic acid A, derived from Rosa rugosa Thunb., is novel inhibitory agent for NF-kappaB and IL-6/STAT3 axis in acute lung injury model.|pdf=|usr=018}}
| |
| − | {{tp|p=32754955|t=2020. Astaxanthin, COVID-19 and immune response: Focus on oxidative stress, apoptosis and autophagy.|pdf=|usr=018}}
| |
| − | {{tp|p=32748969|t=2020. Evaluation of medicinal herbs as a potential therapeutic option against SARS-CoV-2 targeting its main protease.|pdf=|usr=018}}
| |
| − | {{tp|p=32815574|t=2020. Phytotherapeutic options for the treatment of COVID-19: A concise viewpoint.|pdf=|usr=018}}
| |
| − | {{tp|p=32881214|t=2020. Natural products as home-based prophylactic and symptom management agents in the setting of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32785960|t=2020. Traditional and complementary medicine during COVID-19 pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32779305|t=2020. High affinity interaction of Solanum tuberosum and Brassica juncea residue smoke water compounds with proteins involved in coronavirus infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32798764|t=2020. Antiviral properties of placental growth factors: A novel therapeutic approach for COVID-19 treatment.|pdf=|usr=018}}
| |
| − | {{tp|p=32836404|t=2020. Selenium biofortification in the 21(st) century: status and challenges for healthy human nutrition.|pdf=|usr=018}}
| |
| − | {{tp|p=32837491|t=2020. Nonthermal plasma as part of a novel strategy for vaccination.|pdf=|usr=018}}
| |
| − | {{tp|p=32881895|t=2020. COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.|pdf=|usr=018}}
| |
| − | {{tp|p=32726304|t=2020. Developing a low-cost and accessible COVID-19 vaccine for global health.|pdf=|usr=018}}
| |
| − | {{tp|p=32881982|t=2020. Observational study of azithromycin in hospitalized patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32817707|t=2020. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.|pdf=|usr=018}}
| |
| − | {{tp|p=32790733|t=2020. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.|pdf=|usr=018}}
| |
| − | {{tp|p=32785259|t=2020. Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease.|pdf=|usr=018}}
| |
| − | {{tp|p=32749826|t=2020. Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin usage in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32855214|t=2020. Vitamin D status and outcomes for hospitalised older patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32848085|t=2020. Drug repurposing for COVID-19: a potential threat of self-medication and controlling measures.|pdf=|usr=018}}
| |
| − | {{tp|p=32778507|t=2020. COVID-19 and steroid therapy: Impact on diabetes.|pdf=|usr=018}}
| |
| − | {{tp|p=32061635|t=2020. Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus.|pdf=|usr=018}}
| |
| − | {{tp|p=32761523|t=2020. Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase.|pdf=|usr=018}}
| |
| − | {{tp|p=32754890|t=2020. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32871242|t=2020. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32735326|t=2020. Potential role of hypovitaminosis D and Vitamin D supplementation during COVID-19 pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32874905|t=2020. Dexamethasone in severe COVID-19 infection: A case series.|pdf=|usr=018}}
| |
| − | {{tp|p=32868989|t=2020. Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD.|pdf=|usr=018}}
| |
| − | {{tp|p=32759053|t=2020. A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir.|pdf=|usr=018}}
| |
| − | {{tp|p=32836663|t=2020. Melatonina, coronavirus, enfermedad cardiovascular y emergencia geriatrica: inverted exclamation markusemos todo lo que tenemos!|pdf=|usr=018}}
| |
| − | {{tp|p=32768324|t=2020. Melatonin, coronavirus, cardiovascular disease, and the geriatric emergency: let's use everything we have! Response.|pdf=|usr=018}}
| |
| − | {{tp|p=32779326|t=2020. Drugs against SARS-CoV-2: What do we know about their mode of action?|pdf=|usr=018}}
| |
| − | {{tp|p=32880032|t=2020. Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.|pdf=|usr=018}}
| |
| − | {{tp|p=32839635|t=2020. Identification of potential SARS-CoV-2 inhibitors from South African medicinal plant extracts using molecular modelling approaches.|pdf=|usr=018}}
| |
| − | {{tp|p=32834516|t=2020. A phenomenological approach to assessing the effectiveness of COVID-19 related nonpharmaceutical interventions in Germany.|pdf=|usr=018}}
| |
| − | {{tp|p=32813843|t=2020. Study of ongoing registered clinical trials on COVID-19: a narrative review.|pdf=|usr=018}}
| |
| − | {{tp|p=32837217|t=2020. Potential mechanisms of Chinese Herbal Medicine that implicated in the treatment of COVID-19 related renal injury.|pdf=|usr=018}}
| |
| − | {{tp|p=32868970|t=2020. Novel beta-Coronavirus (SARS-CoV-2): Current and Future Aspects of Pharmacological Treatments.|pdf=|usr=018}}
| |
| − | {{tp|p=32797724|t=2020. The potential involvement of P2X7 receptor in COVID-19 pathogenesis: A new therapeutic target?|pdf=|usr=018}}
| |
| − | {{tp|p=32773341|t=2020. Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2?|pdf=|usr=018}}
| |
| − | {{tp|p=32761451|t=2020. Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs.|pdf=|usr=018}}
| |
| − | {{tp|p=32876887|t=2020. Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge.|pdf=|usr=018}}
| |
| − | {{tp|p=32753646|t=2020. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.|pdf=|usr=018}}
| |
| − | {{tp|p=32868801|t=2020. Signal amplification by reversible exchange for COVID-19 antiviral drug candidates.|pdf=|usr=018}}
| |
| − | {{tp|p=32807895|t=2020. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors.|pdf=|usr=018}}
| |
| − | {{tp|p=32792492|t=2020. Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019.|pdf=|usr=018}}
| |
| − | {{tp|p=31705137|t=2019. Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels.|pdf=|usr=018}}
| |
| − | {{tp|p=23594967|t=2013. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin.|pdf=|usr=018}}
| |
| − | {{tp|p=32703908|t=2020. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.|pdf=|usr=018}}
| |
| − | {{tp|p=32855394|t=2020. Promising inhibitors targeting M(pro): an ideal strategy for anti-SARS-CoV-2 drug discovery.|pdf=|usr=018}}
| |
| − | {{tp|p=32855385|t=2020. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.|pdf=|usr=018}}
| |
| − | {{tp|p=32838178|t=2020. Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32838169|t=2020. Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32838168|t=2020. The Central Role of Clinical Nutrition in COVID-19 Patients During and After Hospitalization in Intensive Care Unit.|pdf=|usr=018}}
| |
| − | {{tp|p=32838182|t=2020. Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review.|pdf=|usr=018}}
| |
| − | {{tp|p=32838181|t=2020. Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results.|pdf=|usr=018}}
| |
| − | {{tp|p=32864571|t=2020. Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective.|pdf=|usr=018}}
| |
| − | {{tp|p=32838195|t=2020. Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32838187|t=2020. Protease Inhibitor Use in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32866803|t=2020. Quantum chemical insight into molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT-IR, FT-Raman), drug likeness and molecular docking of the novel anti COVID-19 molecule 2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]-N-(4-fluorophenyl)acetamide - dimer.|pdf=|usr=018}}
| |
| − | {{tp|p=32811531|t=2020. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells.|pdf=|usr=018}}
| |
| − | {{tp|p=32795359|t=2020. Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia.|pdf=|usr=018}}
| |
| − | {{tp|p=32748331|t=2020. Physiological Relevance of Angiotensin Converting Enzyme 2 As a Metabolic Linker and Therapeutic Implication of Mesenchymal Stem Cells in COVID-19 and Hypertension.|pdf=|usr=018}}
| |
| − | {{tp|p=32839921|t=2020. Therapeutic Applications of Stem Cells and Extracellular Vesicles in Emergency Care: Futuristic Perspectives.|pdf=|usr=018}}
| |
| − | {{tp|p=32827081|t=2020. Review of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32815107|t=2020. Epidermal Neural Crest Stem Cells as a Perspective for COVID-19 Treatment.|pdf=|usr=018}}
| |
| − | {{tp|p=32789802|t=2020. Fighting the War Against COVID-19 via Cell-Based Regenerative Medicine: Lessons Learned from 1918 Spanish Flu and Other Previous Pandemics.|pdf=|usr=018}}
| |
| − | {{tp|p=32740890|t=2020. Stem Cells Therapy as a Possible Therapeutic Option in Treating COVID-19 Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32779878|t=2020. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.|pdf=|usr=018}}
| |
| − | {{tp|p=32856432|t=2020. Regen med therapeutic opportunities for fighting COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32820868|t=2020. Coronavirus disease 2019: A tissue engineering and regenerative medicine perspective.|pdf=|usr=018}}
| |
| − | {{tp|p=32808462|t=2020. Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32816059|t=2020. Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review.|pdf=|usr=018}}
| |
| − | {{tp|p=32837118|t=2020. Destabilizing the structural integrity of COVID-19 by caulerpin and its derivatives along with some antiviral drugs: An in silico approaches for a combination therapy.|pdf=|usr=018}}
| |
| − |
| |
| − | {{tp|p=32761294|t=2020. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation.|pdf=|usr=018}}
| |
| − | {{tp|p=32868999|t=2020. Principles Learned from the International Race to Develop a Safe and Effective COVID-19 Vaccine.|pdf=|usr=018}}
| |
| − | {{tp|p=32786284|t=2020. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.|pdf=|usr=018}}
| |
| − | {{tp|p=32743211|t=2020. Prediction of Small Molecule Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus-2 RNA-dependent RNA Polymerase.|pdf=|usr=018}}
| |
| − | {{tp|p=32821885|t=2020. Potential Role of Peptide-Based Antiviral Therapy Against SARS-CoV-2 Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32821882|t=2020. Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir Paradigm.|pdf=|usr=018}}
| |
| − | {{tp|p=32818929|t=2020. Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies.|pdf=|usr=018}}
| |
| − | {{tp|p=32791509|t=2020. G-CSF and GM-CSF Are Different. Which One Is Better for COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32843715|t=2020. Cobrotoxin could be an effective therapeutic for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32747721|t=2020. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32737471|t=2020. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients.|pdf=|usr=018}}
| |
| − | {{tp|p=32863556|t=2020. Covid-19, prise en charge, pistes therapeutiques et vaccinales.|pdf=|usr=018}}
| |
| − | {{tp|p=32838213|t=2020. Rapid production of clinical-grade SARS-CoV-2 specific T cells.|pdf=|usr=018}}
| |
| − | {{tp|p=32837893|t=2020. Efficacy and safety of vitamin C in the management of acute respiratory infection and disease: A rapid review.|pdf=|usr=018}}
| |
| − | {{tp|p=32837891|t=2020. The effect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review.|pdf=|usr=018}}
| |
| − | {{tp|p=32837895|t=2020. Clinical significance summary: Preliminary results of a rapid review of zinc for the prevention and treatment of SARS-CoV-2 and other acute viral respiratory infections.|pdf=|usr=018}}
| |
| − | {{tp|p=32837894|t=2020. The effect of Echinacea spp. on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review.|pdf=|usr=018}}
| |
| − | {{tp|p=32837847|t=2020. A Randomized, Open-label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, A Pilot Study.|pdf=|usr=018}}
| |
| − | {{tp|p=32858566|t=2020. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.|pdf=|usr=018}}
| |
| − | {{tp|p=32852338|t=2020. Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32852340|t=2020. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.|pdf=|usr=018}}
| |
| − | {{tp|p=32871003|t=2020. ASHP principles for COVID-19 vaccine distribution, allocation, and mass immunization.|pdf=|usr=018}}
| |
| − | {{tp|p=32837119|t=2020. Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32746913|t=2020. Clinical practice guidelines and experts' consensuses of traditional Chinese herbal medicine for novel coronavirus (COVID-19): protocol of a systematic review.|pdf=|usr=018}}
| |
| − | {{tp|p=32868957|t=2020. Ultrasound assisted synthesis of 3-alkynyl substituted 2-chloroquinoxaline derivatives: Their in silico assessment as potential ligands for N-protein of SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32834770|t=2020. Favipiravir tautomerism: a theoretical insight.|pdf=|usr=018}}
| |
| − | {{tp|p=32821381|t=2020. Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review.|pdf=|usr=018}}
| |
| − | {{tp|p=32873175|t=2020. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.|pdf=|usr=018}}
| |
| − | {{tp|p=32865158|t=2020. COVID-19 and molecular hydrogen inhalation.|pdf=|usr=018}}
| |
| − | {{tp|p=32865137|t=2020. Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia.|pdf=|usr=018}}
| |
| − | {{tp|p=32684095|t=2020. Worrying situation regarding the use of dexamethasone for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32778854|t=2020. COVID-19: should oral vaccination strategies be given more consideration?|pdf=|usr=018}}
| |
| − | {{tp|p=32801727|t=2020. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date.|pdf=|usr=018}}
| |
| − | {{tp|p=32863947|t=2020. Nanomedicine therapies modulating Macrophage Dysfunction: a potential strategy to attenuate Cytokine Storms in severe infections.|pdf=|usr=018}}
| |
| − | {{tp|p=32747475|t=2020. Tension pneumomediastinum in patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32662203|t=2020. Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32815655|t=2020. Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.|pdf=|usr=018}}
| |
| − | {{tp|p=32888822|t=2020. Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report.|pdf=|usr=018}}
| |
| − | {{tp|p=32713627|t=2020. Convalescent plasma for covid19 - How long should a donor be excluded from donation?|pdf=|usr=018}}
| |
| − | {{tp|p=32878733|t=2020. Convalescent plasma for COVID-19 considerations.|pdf=|usr=018}}
| |
| − | {{tp|p=32883594|t=2020. The successful management of an elderly Covid-19 infected patient by plasmapheresis.|pdf=|usr=018}}
| |
| − | {{tp|p=32883593|t=2020. SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma.|pdf=|usr=018}}
| |
| − | {{tp|p=32771272|t=2020. A Scoping Review of Registered Clinical Trials of Convalescent Plasma for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence (FAST Evidence).|pdf=|usr=018}}
| |
| − | {{tp|p=32770691|t=2020. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32748963|t=2020. Rapid establishment of a COVID-19 convalescent plasma program in a regional health care delivery network.|pdf=|usr=018}}
| |
| − | {{tp|p=32840002|t=2020. Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors.|pdf=|usr=018}}
| |
| − | {{tp|p=32798271|t=2020. Anti-SARS-CoV-2 spike antibodies are stable in convalescent plasma when stored at 4 degrees Celsius for at least 6 weeks.|pdf=|usr=018}}
| |
| − | {{tp|p=32889105|t=2020. Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".|pdf=|usr=018}}
| |
| − | {{tp|p=32739472|t=2020. Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32791213|t=2020. Dexamethasone: A boon for critically ill COVID-19 patients?|pdf=|usr=018}}
| |
| − | {{tp|p=32836826|t=2020. Antiviral potential of garlic (Allium sativum) and its organosulfur compounds: A systematic update of pre-clinical and clinical data.|pdf=|usr=018}}
| |
| − | {{tp|p=32711925|t=2020. Can Activation of NRF2 Be a Strategy against COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32883328|t=2020. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.|pdf=|usr=018}}
| |
| − | {{tp|p=32868985|t=2020. Correlation between immunity from BCG and the morbidity and mortality of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32883062|t=2020. COVID-19 death and BCG vaccination programs worldwide.|pdf=|usr=018}}
| |
| − | {{tp|p=32832735|t=2020. Prolongation of QT interval due to hydroxychloroquine overdose used in COVID-19 treatment.|pdf=|usr=018}}
| |
| − | {{tp|p=32702948|t=2020. Hydroxychloroquine-associated Thrombotic Thrombocytopenic Purpura.|pdf=|usr=018}}
| |
| − | {{tp|p=32718128|t=2020. Perspectives for the immune plasma treatment of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32777902|t=2020. Melatonin, Aging and COVID-19: Could melatonin be beneficial for COVID-19 treatment in elderly?|pdf=|usr=018}}
| |
| − | {{tp|p=32776230|t=2020. Kann Androgendeprivationstherapie eine protektive Rolle bei SARS-CoV-2-Infektionen spielen?|pdf=|usr=018}}
| |
| − | {{tp|p=32863070|t=2020. BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis.|pdf=|usr=018}}
| |
| − | {{tp|p=32798142|t=2020. The effect of Bacillus Calmette-Guerin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: Implications for the COVID-19 pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32875286|t=2020. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?|pdf=|usr=018}}
| |
| − | {{tp|p=32471056|t=2020. The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation.|pdf=|usr=018}}
| |
| − | {{tp|p=32429204|t=2020. Pustulan Activates Chicken Bone Marrow-Derived Dendritic Cells In Vitro and Promotes Ex Vivo CD4(+) T Cell Recall Response to Infectious Bronchitis Virus.|pdf=|usr=018}}
| |
| − | {{tp|p=32731461|t=2020. Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach.|pdf=|usr=018}}
| |
| − | {{tp|p=32717854|t=2020. Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease-Paving the Way for Vaccine Development.|pdf=|usr=018}}
| |
| − | {{tp|p=32707833|t=2020. COVID-19: Mechanisms of Vaccination and Immunity.|pdf=|usr=018}}
| |
| − | {{tp|p=32781672|t=2020. SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID19 Immune Studies and Vaccine Development.|pdf=|usr=018}}
| |
| − | {{tp|p=32781571|t=2020. Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies.|pdf=|usr=018}}
| |
| − | {{tp|p=32872186|t=2020. Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32867098|t=2020. Vaccines against RNA Viruses.|pdf=|usr=018}}
| |
| − | {{tp|p=32854391|t=2020. Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32846910|t=2020. A Scalable Topical Vectored Vaccine Candidate against SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32865701|t=2020. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study.|pdf=|usr=018}}
| |
| − | {{tp|p=32882638|t=2020. Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32768490|t=2020. Melatonin potentials against viral infections including COVID-19: Current evidence and new findings.|pdf=|usr=018}}
| |
| − | {{tp|p=32717346|t=2020. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.|pdf=|usr=018}}
| |
| − | {{tp|p=32866534|t=2020. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32866536|t=2020. Association of vitamin D with the modulation of the disease severity in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32846196|t=2020. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.|pdf=|usr=018}}
| |
| − | {{tp|p=32827627|t=2020. Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32800805|t=2020. COVID-19 Vaccine: A comprehensive status report.|pdf=|usr=018}}
| |
| − | {{tp|p=31560964|t=2019. Antiviral activity of Sambucus FormosanaNakai ethanol extract and related phenolic acid constituents against human coronavirus NL63.|pdf=|usr=018}}
| |
| − | {{tp|p=32722574|t=2020. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32674326|t=2020. Temperature Sensitivity: A Potential Method for the Generation of Vaccines against the Avian Coronavirus Infectious Bronchitis Virus.|pdf=|usr=018}}
| |
| − | {{tp|p=31968702|t=2020. Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice.|pdf=|usr=018}}
| |
| − | {{tp|p=32784685|t=2020. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?|pdf=|usr=018}}
| |
| − | {{tp|p=32859008|t=2020. Optimization Rules for SARS-CoV-2 M(pro) Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.|pdf=|usr=018}}
| |
| − | {{tp|p=32726230|t=2020. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.|pdf=|usr=018}}
| |
| − | {{tp|p=32726238|t=2020. Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.|pdf=|usr=018}}
| |
| − | {{tp|p=32734479|t=2020. Partially ionized medical oxygen as a supplementary treatment for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32776298|t=2020. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.|pdf=|usr=018}}
| |
| − | {{tp|p=32837110|t=2020. 42 cases of coronavirus disease 2019 of the ordinary type with the adjuvant treatment of heat-sensitive moxibustion 42.|pdf=|usr=018}}
| |
| − | {{tp|p=32837109|t=2020. Case of professor Xu ZOU's acupuncture technique for "benefiting kidney and strengthening anti-pathogenic qi" in promoting the absorption of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32837108|t=2020. Two cases of corona virus disease 2019 (COVID-19) treated with the combination of acupuncture and medication in bedridden patients2.|pdf=|usr=018}}
| |
| − | {{tp|p=32837107|t=2020. Thoughts on the effects of moxa smoke in the epidemic prevention.|pdf=|usr=018}}
| |
| − | {{tp|p=32742564|t=2020. Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32832877|t=2020. Polymonoclonal (Not Polyclonal) Antibodies Derived from Convalescent Human B Cell Hybridomas Might Be a Better Therapeutic Option than Single Target Monoclonal Antibodies.|pdf=|usr=018}}
| |
| − | {{tp|p=32726783|t=2020. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=31955138|t=2020. Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors.|pdf=|usr=018}}
| |
| − | {{tp|p=32551793|t=2020. Recent advances in vaccines and diagnostics against Middle East respiratory syndrome coronavirus.|pdf=|usr=018}}
| |
| − | {{tp|p=32761570|t=2020. Epithelial Dysfunction in Lung Diseases: Effects of Amino Acids and Potential Mechanisms.|pdf=|usr=018}}
| |
| − | {{tp|p=32875709|t=2020. Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo.|pdf=|usr=018}}
| |
| − | {{tp|p=32864794|t=2020. Particulate Alum via Pickering Emulsion for an Enhanced COVID-19 Vaccine Adjuvant.|pdf=|usr=018}}
| |
| − | {{tp|p=32726479|t=2020. Bacillus Calmette-Guerin vaccination and socioeconomic variables vs COVID-19 global features: Clearing up a controversial issue.|pdf=|usr=018}}
| |
| − | {{tp|p=32827405|t=2020. Are Medicinal Plants an Alternative Strategy to Combat COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32827400|t=2020. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32845250|t=2020. COVID-19: Prospective Challenges and Potential Vaccines.|pdf=|usr=018}}
| |
| − | {{tp|p=32668969|t=2020. Potential Targets for Treatment of Coronavirus Disease 2019 (COVID-19): A Review of Qing-Fei-Pai-Du-Tang and Its Major Herbs.|pdf=|usr=018}}
| |
| − | {{tp|p=32839815|t=2020. COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.|pdf=|usr=018}}
| |
| − | {{tp|p=32631576|t=2020. Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.|pdf=|usr=018}}
| |
| − |
| |
| − | {{tp|p=32805728|t=2020. Revealing the targets and mechanisms of vitamin A in the treatment of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32876941|t=2020. Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32865757|t=2020. Cytokine storm in aged people with CoV-2: possible role of vitamins as therapy or preventive strategy.|pdf=|usr=018}}
| |
| − | {{tp|p=32797388|t=2020. Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak.|pdf=|usr=018}}
| |
| − | {{tp|p=32765941|t=2020. Bioactive Lipids as Mediators of the Beneficial Action(s) of Mesenchymal Stem Cells in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32765939|t=2020. COVID-19 and Senotherapeutics: Any Role for the Naturally-occurring Dipeptide Carnosine?|pdf=|usr=018}}
| |
| − | {{tp|p=32765938|t=2020. Potential Using of Fat-derived Stromal Cells in the Treatment of Active Disease, and also, in Both Pre- and Post-Periods in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32656827|t=2020. Letter: ACE2, Rho kinase inhibition and the potential role of vitamin D against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32762135|t=2020. Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32774998|t=2020. Principles and treatment strategies for the use of Chinese herbal medicine in patients at different stages of coronavirus infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32737841|t=2020. Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?|pdf=|usr=018}}
| |
| − | {{tp|p=32804917|t=2020. Potential Role of Oxygen-Ozone Therapy in Treatment of COVID-19 Pneumonia.|pdf=|usr=018}}
| |
| − | {{tp|p=32865522|t=2020. A 57-Year-Old African American Man with Severe COVID-19 Pneumonia Who Responded to Supportive Photobiomodulation Therapy (PBMT): First Use of PBMT in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32796809|t=2020. Short-Term Corticosteroid Therapy for Early Exacerbation of COVID-19 Pneumonia: A Case Report.|pdf=|usr=018}}
| |
| − | {{tp|p=32616373|t=2020. The influence of corticosteroid on patients with COVID-19 infection: A meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32795424|t=2020. Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality.|pdf=|usr=018}}
| |
| − | {{tp|p=32755302|t=2020. Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)?|pdf=|usr=018}}
| |
| − | {{tp|p=32787704|t=2020. Reply to Jakovac and to Rocha et al.: Can vitamin D prevent or manage COVID-19 illness?|pdf=|usr=018}}
| |
| − | {{tp|p=32672049|t=2020. Reply to Jakovac: COVID-19, vitamin D, and type I interferon.|pdf=|usr=018}}
| |
| − | {{tp|p=32778354|t=2020. Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention.|pdf=|usr=018}}
| |
| − | {{tp|p=32841477|t=2020. Allosteric inhibition of the SARS-CoV-2 main protease - insights from mass spectrometry-based assays.|pdf=|usr=018}}
| |
| − | {{tp|p=32878641|t=2020. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32805515|t=2020. Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG vaccine.|pdf=|usr=018}}
| |
| − | {{tp|p=32866405|t=2020. Web Exclusive. Annals On Call - Regulatory T Cells: Treatment for COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32730105|t=2020. Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.|pdf=|usr=018}}
| |
| − | {{tp|p=32853033|t=2020. Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32737995|t=2020. Reply to the Letter "COVID-19-Associated Encephalopathy and Cytokine-Mediated Neuroinflammation".|pdf=|usr=018}}
| |
| − | {{tp|p=32822832|t=2020. Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy.|pdf=|usr=018}}
| |
| − | {{tp|p=32787379|t=2020. Overview of prognostic factors in adult gliomas|pdf=|usr=018}}
| |
| − | {{tp|p=32819125|t=2020. Epidemiology and clinical characteristics of 43 COVID-19 patients in Weifang, China.|pdf=|usr=018}}
| |
| − | {{tp|p=32787373|t=2020. Modified rehabilitation exercises for mild cases of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32863659|t=2020. Patterns of myocardial involvement in children during COVID-19 pandemic: Early experience from northern Italy.|pdf=|usr=018}}
| |
| − | {{tp|p=32719045|t=2020. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.|pdf=|usr=018}}
| |
| − | {{tp|p=32732245|t=2020. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.|pdf=|usr=018}}
| |
| − | {{tp|p=32855151|t=2020. Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: 'Colchicine treatment in community healthcare setting to prevent severe COVID-19' by Della-Torre et al.|pdf=|usr=018}}
| |
| − | {{tp|p=32831940|t=2020. Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32831932|t=2020. Amphotericin B as antiviral drug: Possible efficacy against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32890967|t=2020. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32761219|t=2020. Convalescent plasma to treat COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32790855|t=2020. Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.|pdf=|usr=018}}
| |
| − | {{tp|p=32889088|t=2020. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries.|pdf=|usr=018}}
| |
| − | {{tp|p=32881062|t=2020. Hypothesis: The Potential Therapeutic Role of Nicorandil in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32881059|t=2020. A novel concept for treatment and vaccination against Covid-19 with an inhaled chitosan-coated DNA vaccine encoding a secreted spike protein portion.|pdf=|usr=018}}
| |
| − | {{tp|p=32857836|t=2020. Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers.|pdf=|usr=018}}
| |
| − | {{tp|p=32845289|t=2020. Methylprednisolone for COVID-19: Was Benjamin Rush prescient?|pdf=|usr=018}}
| |
| − | {{tp|p=32829400|t=2020. BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden.|pdf=|usr=018}}
| |
| − | {{tp|p=32869854|t=2020. Using serpins cysteine protease cross-specificity to possibly trap SARS-CoV-2 Mpro with reactive center loop chimera.|pdf=|usr=018}}
| |
| − | {{tp|p=32622469|t=2020. Is Inhaled Furosemide a Potential Therapeutic for COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32750259|t=2020. COVID-19: Clean up on IL-6.|pdf=|usr=018}}
| |
| − | {{tp|p=32857620|t=2020. Azithromycin Downregulates Gene Expression of IL-1beta and Pathways Involving TMPRSS2 and TMPRSS11D Required by SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32853024|t=2020. Immune Modulation to Improve Survival of Viral Pneumonia in Mice.|pdf=|usr=018}}
| |
| − | {{tp|p=32755507|t=2020. Rewiring the Immune Response in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32886840|t=2020. Overcoming Symmetry Mismatch in Vaccine Nanoassembly via Spontaneous Amidation.|pdf=|usr=018}}
| |
| − | {{tp|p=32870563|t=2020. Catalytic Asymmetric Synthesis of the Anti-COVID-19 Drug Remdesivir.|pdf=|usr=018}}
| |
| − | {{tp|p=32729180|t=2020. Molecular Insights into Small Molecule Drug Discovery for SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32864982|t=2020. Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32735169|t=2020. Deploying Randomized Controlled Trials during the COVID-19 Pandemic: Reason and Bayesian Designs.|pdf=|usr=018}}
| |
| − | {{tp|p=32581018|t=2020. Could Demodex Be Used to Augment a Topical Vaccine Against Coronavirus (and Similar Viruses)?|pdf=|usr=018}}
| |
| − | {{tp|p=32737112|t=2020. Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.|pdf=|usr=018}}
| |
| − | {{tp|p=32737108|t=2020. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.|pdf=|usr=018}}
| |
| − | {{tp|p=32737107|t=2020. More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia.|pdf=|usr=018}}
| |
| − | {{tp|p=32737106|t=2020. Rational use of tocilizumab in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32737105|t=2020. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli.|pdf=|usr=018}}
| |
| − | {{tp|p=32759263|t=2020. Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis.|pdf=|usr=018}}
| |
| − | {{tp|p=32753421|t=2020. Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci et al.|pdf=|usr=018}}
| |
| − | {{tp|p=32753417|t=2020. Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al.|pdf=|usr=018}}
| |
| − | {{tp|p=32855152|t=2020. Colchicine treatment in community healthcare setting to prevent severe COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32816702|t=2020. Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: 'Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al' by Cheng and Zhang.|pdf=|usr=018}}
| |
| − | {{tp|p=32816701|t=2020. High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab.|pdf=|usr=018}}
| |
| − | {{tp|p=32816700|t=2020. Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al.|pdf=|usr=018}}
| |
| − | {{tp|p=32816698|t=2020. Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al.|pdf=|usr=018}}
| |
| − | {{tp|p=32759267|t=2020. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.|pdf=|usr=018}}
| |
| − | {{tp|p=32868327|t=2020. Removal of remdesivir's metabolite GS-441524 by hemodialysis in a double lung transplant recipient with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32744511|t=2020. Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system.|pdf=|usr=018}}
| |
| − | {{tp|p=32538803|t=2020. Implementacion de la teleconsulta en la practica urologica durante la era Covid-19: inverted question markque hemos aprendido?|pdf=|usr=018}}
| |
| − | {{tp|p=32725790|t=2020. Synergy between cytokines and risk factors in the cytokine storm of Covid-19: protection from the chronic use of cytokine inhibitors?|pdf=|usr=018}}
| |
| − | {{tp|p=32882061|t=2020. Hyperferritinemia in patients with COVID-19: An opportunity for iron chelation?|pdf=|usr=018}}
| |
| − | {{tp|p=32701630|t=2020. Treatment of Cytokine Storm in COVID-19 Patients with Immunomodulatory Therapy.|pdf=|usr=018}}
| |
| − | {{tp|p=32740071|t=2020. A Word of Caution in the Use of Hydroxychloroquine in the Elderly COVID-19 Population.|pdf=|usr=018}}
| |
| − | {{tp|p=32740070|t=2020. Chloroquine, Hydroxychloroquine, Retinal Toxicity, and COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32887677|t=2020. Covid-19: Hydrocortisone can be used as alternative to dexamethasone, review finds.|pdf=|usr=018}}
| |
| − | {{tp|p=32732352|t=2020. Remdesivir for severe covid-19: a clinical practice guideline.|pdf=|usr=018}}
| |
| − | {{tp|p=32759299|t=2020. Covid-19: Where are we on immunity and vaccines?|pdf=|usr=018}}
| |
| − | {{tp|p=32843352|t=2020. Include pregnant women in research-particularly covid-19 research.|pdf=|usr=018}}
| |
| − | {{tp|p=32843328|t=2020. Covid-19: US approves emergency use of convalescent plasma despite warnings over lack of evidence.|pdf=|usr=018}}
| |
| − | {{tp|p=32839191|t=2020. Russian SARS-CoV-2 vaccine.|pdf=|usr=018}}
| |
| − | {{tp|p=32816760|t=2020. The rush to create a covid-19 vaccine may do more harm than good.|pdf=|usr=018}}
| |
| − | {{tp|p=32816758|t=2020. Covid-19: Russia approves vaccine without large scale testing or published results.|pdf=|usr=018}}
| |
| − | {{tp|p=32881064|t=2020. Beyond Dexamethasone, Emerging Immuno-Thrombotic Therapies for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32820554|t=2020. Prescribing in COVID-19 patients: Should we take into account inflammation?|pdf=|usr=018}}
| |
| − | {{tp|p=32758306|t=2020. Selenium and viral infection: are there lessons for COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32843118|t=2020. Nutritional status, diet and viral respiratory infections: perspectives for SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32815493|t=2020. Nutritional status of micronutrients as a possible and modifiable risk factor for COVID-19: a UK perspective.|pdf=|usr=018}}
| |
| − | {{tp|p=32656343|t=2020. Cannabinoids and the Coronavirus.|pdf=|usr=018}}
| |
| − | {{tp|p=32769401|t=2020. Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?|pdf=|usr=018}}
| |
| − | {{tp|p=32773440|t=2020. A Review of Remdesivir for COVID-19: Data to Date.|pdf=|usr=018}}
| |
| − | {{tp|p=32745524|t=2020. Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.|pdf=|usr=018}}
| |
| − | {{tp|p=32886768|t=2020. Therapy of Sars-Coronavirus-2 pneumonia: is there an optimal IL-6 cut-off for successful tocilizumab treatment?|pdf=|usr=018}}
| |
| − | {{tp|p=32886762|t=2020. Efficacy of Tocilizumab for treatment of severe COVID-19 Pneumonia: more evidence is needed.|pdf=|usr=018}}
| |
| − | {{tp|p=32674139|t=2020. The Value of Human Challenges in SARS-2-nCoV Vaccine Development.|pdf=|usr=018}}
| |
| − | {{tp|p=32863274|t=2020. Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32863273|t=2020. Antiviral treatment for COVID-19: the evidence supporting remdesivir.|pdf=|usr=018}}
| |
| − | {{tp|p=32859332|t=2020. Easy-to-prescribe nutrition support in the intensive care in the era of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32881661|t=2020. Discovery of Some Antiviral Natural products to fight against Novel Corona Virus (SARS-CoV-2) using Insilico approach.|pdf=|usr=018}}
| |
| − | {{tp|p=32748740|t=2020. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking Screening.|pdf=|usr=018}}
| |
| − | {{tp|p=32723229|t=2020. Could Targeting HMGB1 be useful for the Clinical Management of COVID-19 Infection?|pdf=|usr=018}}
| |
| − | {{tp|p=32767929|t=2020. Theoretical Study of the Molecular Mechanism of Maxingyigan Decoction Against COVID-19: Network Pharmacology-based Strategy.|pdf=|usr=018}}
| |
| − | {{tp|p=32838713|t=2020. The Antiviral and Antimalarial Drug Repurposing in Quest of Chemotherapeutics to Combat COVID-19 Utilizing Structure-Based Molecular Docking.|pdf=|usr=018}}
| |
| − | {{tp|p=32819226|t=2020. Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials against COVID-19: An in-silico Evaluation.|pdf=|usr=018}}
| |
| − | {{tp|p=32807047|t=2020. Potential Leads from Liquorice against SARS-CoV-2 Main Protease using Molecular Docking Simulation Studies.|pdf=|usr=018}}
| |
| − | {{tp|p=32798373|t=2020. Molecular Docking and Virtual Screening based prediction of drugs for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32769050|t=2020. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.|pdf=|usr=018}}
| |
| − |
| |
| − | {{tp|p=32793725|t=2020. Tocilizumab exerts anti-inflammatory activity in six critically ill COVID-19 patients: a retrospective analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=31690009|t=2019. Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV.|pdf=|usr=018}}
| |
| − | {{tp|p=32722164|t=2020. Flavonoids Activation of the Transcription Factor Nrf2 as a Hypothesis Approach for the Prevention and Modulation of SARS-CoV-2 Infection Severity.|pdf=|usr=018}}
| |
| − | {{tp|p=32823497|t=2020. Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits.|pdf=|usr=018}}
| |
| − | {{tp|p=32739404|t=2020. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.|pdf=|usr=018}}
| |
| − | {{tp|p=31863793|t=2020. In silico and in vitro analysis of small molecules and natural compounds targeting the 3CL protease of feline infectious peritonitis virus.|pdf=|usr=018}}
| |
| − | {{tp|p=31765674|t=2020. Decoupling deISGylating and deubiquitinating activities of the MERS virus papain-like protease.|pdf=|usr=018}}
| |
| − | {{tp|p=32763313|t=2020. Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.|pdf=|usr=018}}
| |
| − | {{tp|p=32854147|t=2020. Can a gluten-free diet be partly protective for covid-19 infection?|pdf=|usr=018}}
| |
| − | {{tp|p=32813067|t=2020. Construction of an infectious bronchitis virus vaccine strain carrying chimeric S1 gene of a virulent isolate and its pathogenicity analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32813065|t=2020. Role of probiotics to combat viral infections with emphasis on COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32836625|t=2020. Quantum dots as a promising agent to combat COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32733978|t=2020. How to Boost our Immune System Against Coronavirus Infection?|pdf=|usr=018}}
| |
| − | {{tp|p=32837201|t=2020. Inefficacite et dangerosite potentielle de l'hydroxychloroquine pour traiter une infection par le coronavirus Sars-cov2.|pdf=|usr=018}}
| |
| − | {{tp|p=32723524|t=2020. Response to: Amantadine, COVID-19 and Parkinsonism.|pdf=|usr=018}}
| |
| − | {{tp|p=32863034|t=2020. A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32818235|t=2020. Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers.|pdf=|usr=018}}
| |
| − | {{tp|p=32740801|t=2020. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32808185|t=2020. Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue.|pdf=|usr=018}}
| |
| − | {{tp|p=31950289|t=2020. Recombinant adenovirus carrying a core neutralizing epitope of porcine epidemic diarrhea virus and heat-labile enterotoxin B of Escherichia coli as a mucosal vaccine.|pdf=|usr=018}}
| |
| − | {{tp|p=32253616|t=2020. A flagellin-adjuvanted inactivated porcine epidemic diarrhea virus (PEDV) vaccine provides enhanced immune protection against PEDV challenge in piglets.|pdf=|usr=018}}
| |
| − | {{tp|p=32741139|t=2020. Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32779737|t=2020. The absorbing filter Oxiris in severe COVID-19 patients: A case series.|pdf=|usr=018}}
| |
| − | {{tp|p=32674226|t=2020. Covid-19 and dietary socioecology: Risk minimisation.|pdf=|usr=018}}
| |
| − | {{tp|p=32828312|t=2020. Establishment and validation of a drug-target microarray for SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32592721|t=2020. Natural cardenolides suppress coronaviral replication by downregulating JAK1 via a Na(+)/K(+)-ATPase independent proteolysise.|pdf=|usr=018}}
| |
| − | {{tp|p=32739342|t=2020. COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32786401|t=2020. A Chemoenzymatic Synthesis of the (RP)-Isomer of the Antiviral Prodrug Remdesivir.|pdf=|usr=018}}
| |
| − | {{tp|p=32805303|t=2020. Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon?|pdf=|usr=018}}
| |
| − | {{tp|p=32743022|t=2020. Targeting the cholinergic anti-inflammatory pathway with vagus nerve stimulation in patients with Covid-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32815593|t=2020. Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32793443|t=2020. Computational-based drug repurposing methods in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32683439|t=2020. protein-sol pKa: prediction of electrostatic frustration, with application to coronaviruses.|pdf=|usr=018}}
| |
| − | {{tp|p=32831527|t=2020. Views on Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease by Dai et al. (2020).|pdf=|usr=018}}
| |
| − | {{tp|p=32831526|t=2020. Comments on Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease by Dai et al.(2020).|pdf=|usr=018}}
| |
| − | {{tp|p=32831523|t=2020. Molecular docking analysis of Withaferin A from Withania somnifera with the Glucose regulated protein 78 (GRP78) receptor and the SARS-CoV-2 main protease.|pdf=|usr=018}}
| |
| − | {{tp|p=32831522|t=2020. Molecular docking analysis of N-substituted Oseltamivir derivatives with the SARS-CoV-2 main protease.|pdf=|usr=018}}
| |
| − | {{tp|p=32831518|t=2020. Towards the design of epitope candidates for Coronavirus 2.|pdf=|usr=018}}
| |
| − | {{tp|p=32773989|t=2020. Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32878881|t=2020. Denovo designing, retrosynthetic analysis, and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2.|pdf=|usr=018}}
| |
| − | {{tp|p=32754003|t=2020. Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review.|pdf=|usr=018}}
| |
| − | {{tp|p=32731331|t=2020. The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections.|pdf=|usr=018}}
| |
| − | {{tp|p=32846906|t=2020. Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?|pdf=|usr=018}}
| |
| − | {{tp|p=32792167|t=2020. Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19).|pdf=|usr=018}}
| |
| − | {{tp|p=32763818|t=2020. Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32736237|t=2020. Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience.|pdf=|usr=018}}
| |
| − | {{tp|p=32861965|t=2020. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32881296|t=2020. A Cytometrist's Guide to Coordinating and Performing Effective COVID-19 Research.|pdf=|usr=018}}
| |
| − | {{tp|p=32882643|t=2020. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32889063|t=2020. Could PROTACs Protect Us From COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32880807|t=2020. Comment on: "Pharmaco-Immunomodulatory Therapy in COVID-19".|pdf=|usr=018}}
| |
| − | {{tp|p=32880806|t=2020. Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy I COVID-19".|pdf=|usr=018}}
| |
| − | {{tp|p=32882216|t=2020. The prophylaxis and treatment potential of supplements for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32829416|t=2020. The Case for Re-Examining Glycosylation Inhibitors, Mimetics, Primers and Glycosylation Decoys as Antivirals and Anti-Inflammatories in COVID19.|pdf=|usr=018}}
| |
| − | {{tp|p=32870053|t=2020. Comment on "Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic."|pdf=|usr=018}}
| |
| − | {{tp|p=32888379|t=2020. Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs.|pdf=|usr=018}}
| |
| − | {{tp|p=32881359|t=2020. Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-label Randomized Controlled Pilot Study.|pdf=|usr=018}}
| |
| − | {{tp|p=32881340|t=2020. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study.|pdf=|usr=018}}
| |
| − | {{tp|p=32815389|t=2020. A concern about survival time as an endpoint in coronavirus disease 2019 clinical trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32815379|t=2020. COVID-19 impact on multi-site recruitment and enrollment.|pdf=|usr=018}}
| |
| − | {{tp|p=32833695|t=2020. Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With Coronavirus Disease 2019 Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32833772|t=2020. Therapeutic Options for the Treatment of Coronavirus Disease (COVID-19).|pdf=|usr=018}}
| |
| − | {{tp|p=32860358|t=2020. Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: An alternative to COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32867652|t=2020. Feasibility of mesenchymal stem cell therapy for COVID-19:A mini review.|pdf=|usr=018}}
| |
| − | {{tp|p=32881656|t=2020. Targeting COVID-19 in Parkinson's patients: Drugs repurposed.|pdf=|usr=018}}
| |
| − | {{tp|p=32693756|t=2020. Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32867666|t=2020. COVID-19: Pathophysiology; Mechanism of Transmission and Possible Molecular Drug Target for Management.|pdf=|usr=018}}
| |
| − | {{tp|p=32767920|t=2020. The Plausible role of Indian Traditional Medicine in combating Corona Virus (SARS-CoV 2): a mini-review.|pdf=|usr=018}}
| |
| − | {{tp|p=32867651|t=2020. Repositioning of drugs to counter COVID-19 pandemic - An Insight.|pdf=|usr=018}}
| |
| − | {{tp|p=32881659|t=2020. Targeting Natural Products for the Treatment of COVID-19 - An Updated Review.|pdf=|usr=018}}
| |
| − | {{tp|p=32867645|t=2020. Neutralization of SARS-CoV-2 Spike Protein via Natural Compounds: A Multi Layered High Throughput Virtual Screening Approach.|pdf=|usr=018}}
| |
| − | {{tp|p=32787748|t=2020. Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the "Cytokine Release (Storm) Syndrome" Caused by SARS-CoV-2?|pdf=|usr=018}}
| |
| − | {{tp|p=32729428|t=2020. The Promise of Mesenchymal stem cells therapy for acute Respiratory Distress Syndrome Caused by COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32729640|t=2020. Probing 3CL protease: Rationally designed chemical moieties for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32877948|t=2020. The Potential Therapeutic Role of Proton Pump Inhibitors in COVID-19: Hypotheses Based on Existing Evidences.|pdf=|usr=018}}
| |
| − | {{tp|p=32875990|t=2020. Exploitation of some natural products for prevention and/or nutritional treatment of SARS-CoV2 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32755992|t=2020. MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32886952|t=2020. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.|pdf=|usr=018}}
| |
| − | {{tp|p=32739174|t=2020. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32295404|t=2020. Amiodarone as a possible therapy for coronavirus infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32633332|t=2020. The complement inhibitors in COVID-19: future expectations.|pdf=|usr=018}}
| |
| − | {{tp|p=32744716|t=2020. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.|pdf=|usr=018}}
| |
| − | {{tp|p=32744711|t=2020. Molecular modelling of the antiviral action of Resveratrol derivatives against the activity of two novel SARS CoV-2 and 2019-nCoV receptors.|pdf=|usr=018}}
| |
| − | {{tp|p=32767353|t=2020. Morning vs. evening administration of antiviral therapy in COVID-19 patients. A preliminary retrospective study in Ferrara, Italy.|pdf=|usr=018}}
| |
| − | {{tp|p=32767349|t=2020. Corticosteroid therapy for patients with severe novel Coronavirus disease 2019.|pdf=|usr=018}}
| |
| − | {{tp|p=32767348|t=2020. Inhibitory effects of Vitamin D on inflammation and IL-6 release. A further support for COVID-19 management?|pdf=|usr=018}}
| |
| − | {{tp|p=32767316|t=2020. Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA).|pdf=|usr=018}}
| |
| − | {{tp|p=32866053|t=2020. The effect of drugs used in rheumatology for treating SARS-CoV2 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32744917|t=2020. Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects.|pdf=|usr=018}}
| |
| − | {{tp|p=32820694|t=2020. Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine-promising therapeutic strategy for SARS-CoV-2 treatment.|pdf=|usr=018}}
| |
| − | {{tp|p=32877233|t=2020. A public-private partnership for the express development of antiviral leads: a perspective view.|pdf=|usr=018}}
| |
| − | {{tp|p=32840116|t=2020. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32799566|t=2020. Emerging therapeutics for the management of COVID 19.|pdf=|usr=018}}
| |
| − | {{tp|p=32752970|t=2020. The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications.|pdf=|usr=018}}
| |
| − | {{tp|p=32887532|t=2020. Inhibitors of Type II transmembrane serine proteases in the treatment of diseases of the respiratory tract - A review of patent literature.|pdf=|usr=018}}
| |
| − | {{tp|p=32814446|t=2020. COVID-19: fighting the invisible enemy with microRNAs.|pdf=|usr=018}}
| |
| − | {{tp|p=32853038|t=2020. Azithromycin in the treatment of COVID-19: a review.|pdf=|usr=018}}
| |
| − | {{tp|p=32809870|t=2020. MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale.|pdf=|usr=018}}
| |
| − | {{tp|p=32795214|t=2020. Ongoing non-industry-sponsored COVID-19 clinical trials in the first trimester of the pandemic: significant differences between the European and the USA approaches.|pdf=|usr=018}}
| |
| − | {{tp|p=32746653|t=2020. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.|pdf=|usr=018}}
| |
| − | {{tp|p=32729363|t=2020. Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs.|pdf=|usr=018}}
| |
| − | {{tp|p=32734777|t=2020. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32815406|t=2020. Exploring the SARS-CoV-2 structural proteins for multi-epitope vaccine development: an in-silico approach.|pdf=|usr=018}}
| |
| − | {{tp|p=32842811|t=2020. An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies.|pdf=|usr=018}}
| |
| − | {{tp|p=32869699|t=2020. Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32838605|t=2020. Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.|pdf=|usr=018}}
| |
| − | {{tp|p=32776374|t=2020. AMPK activation by ozone therapy inhibits tissue factor-triggered intestinal ischemia and ameliorates chemotherapeutic enteritis.|pdf=|usr=018}}
| |
| − | {{tp|p=32831340|t=2020. Optimizacion de la terapia nutricional en el paciente critico con COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32831329|t=2020. COVID-19 y la nutricion clinica. inverted question markPor que es importante?|pdf=|usr=018}}
| |
| − | {{tp|p=32745502|t=2020. Probing antiviral drugs against SARS-CoV-2 through virus-drug association prediction based on the KATZ method.|pdf=|usr=018}}
| |
| − | {{tp|p=32536610|t=2020. Contrasting evidence for corticosteroid treatment for coronavirus-induced cytokine storm.|pdf=|usr=018}}
| |
| − | {{tp|p=32742008|t=2020. Repurposed Drugs Against COVID-19: Safety Concerns and Stockout.|pdf=|usr=018}}
| |
| − |
| |
| − | {{tp|p=32846329|t=2020. Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents.|pdf=|usr=018}}
| |
| − | {{tp|p=32768882|t=2020. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.|pdf=|usr=018}}
| |
| − | {{tp|p=32781796|t=2020. Arginine and Endothelial Function.|pdf=|usr=018}}
| |
| − | {{tp|p=32126736|t=2020. Small Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Fusion by Targeting Cavities on Heptad Repeat Trimers.|pdf=|usr=018}}
| |
| − | {{tp|p=32825327|t=2020. Melatonin's Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease.|pdf=|usr=018}}
| |
| − | {{tp|p=32796765|t=2020. Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101).|pdf=|usr=018}}
| |
| − | {{tp|p=31690059|t=2019. Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells.|pdf=|usr=018}}
| |
| − | {{tp|p=32781216|t=2020. Identification of 4-anilino-6-aminoquinazoline derivatives as potential MERS-CoV inhibitors.|pdf=|usr=018}}
| |
| − | {{tp|p=31624041|t=2019. Synthesis and biological evaluation of 3-acyl-2-phenylamino-1,4-dihydroquinolin-4(1H)-one derivatives as potential MERS-CoV inhibitors.|pdf=|usr=018}}
| |
| − | {{tp|p=32718376|t=2020. Clozapine and COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32340021|t=2020. Early Leukapheresis Depletion in an Ex-Premature with Severe Acute Respiratory Distress Syndrome Due to Bordetella Pertussis and Coronavirus Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32854985|t=2020. Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?|pdf=|usr=018}}
| |
| − | {{tp|p=32731913|t=2020. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment.|pdf=|usr=018}}
| |
| − | {{tp|p=32807087|t=2020. Improving the impact of non-pharmaceutical interventions during COVID-19: examining the factors that influence engagement and the impact on individuals.|pdf=|usr=018}}
| |
| − | {{tp|p=32867708|t=2020. Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32819292|t=2020. Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19).|pdf=|usr=018}}
| |
| − | {{tp|p=32883368|t=2020. A protein interaction map identifies existing drugs targeting SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32732190|t=2020. Drug treatments for covid-19: living systematic review and network meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32764129|t=2020. Patient-centric research in the time of COVID-19: conducting ethical COVID-19 research in Africa.|pdf=|usr=018}}
| |
| − | {{tp|p=32816957|t=2020. Bowel ulceration following tocilizumab administration in a COVID-19 patient.|pdf=|usr=018}}
| |
| − | {{tp|p=32818151|t=2020. Virucidal benefits of povidone-iodine use on the ocular surface: a review.|pdf=|usr=018}}
| |
| − | {{tp|p=32792138|t=2020. A novel role for lidocaine in COVID-19 patients?|pdf=|usr=018}}
| |
| − | {{tp|p=32779815|t=2020. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32730151|t=2020. Time-critical administration of corticosteroid rescue therapy for COVID-19 pneumonitis in a ward-based patient with chronic obstructive pulmonary disease.|pdf=|usr=018}}
| |
| − | {{tp|p=32859459|t=2020. Use of mouthwashes against COVID-19 in dentistry.|pdf=|usr=018}}
| |
| − | {{tp|p=32783196|t=2020. Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H2 S donors in COVID-19 therapy.|pdf=|usr=018}}
| |
| − | {{tp|p=32757447|t=2020. COVID-19 and gastrointestinal symptoms.|pdf=|usr=018}}
| |
| − | {{tp|p=32883935|t=2020. Genomic evolution of severe acute respiratory syndrome Coronavirus 2 in India and vaccine impact.|pdf=|usr=018}}
| |
| − | {{tp|p=32859863|t=2020. Will bacille Calmette-Guerin immunization arrest the COVID-19 pandemic?|pdf=|usr=018}}
| |
| − | {{tp|p=32811798|t=2020. Hydroxychloroquine for prophylaxis in COVID-19: Need to revisit dosing regimen.|pdf=|usr=018}}
| |
| − | {{tp|p=32773415|t=2020. Hydroxychloroquine for chemoprophylaxis in COVID-19: A case of motivated perception?|pdf=|usr=018}}
| |
| − | {{tp|p=32773410|t=2020. Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers.|pdf=|usr=018}}
| |
| − | {{tp|p=32880819|t=2020. Vaccine Against Covid-19 Disease - Present Status of Development.|pdf=|usr=018}}
| |
| − | {{tp|p=32882432|t=2020. Genome based evolutionary lineage of SARS-CoV-2 towards the development of novel chimeric vaccine.|pdf=|usr=018}}
| |
| − | {{tp|p=32889241|t=2020. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.|pdf=|usr=018}}
| |
| − | {{tp|p=32889236|t=2020. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.|pdf=|usr=018}}
| |
| − | {{tp|p=32829390|t=2020. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU.|pdf=|usr=018}}
| |
| − | {{tp|p=32880390|t=2020. Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan, China.|pdf=|usr=018}}
| |
| − | {{tp|p=32881641|t=2020. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32880510|t=2020. Intravescical instillation of Calmette-Guerin bacillus and COVID-19 risk.|pdf=|usr=018}}
| |
| − | {{tp|p=32762516|t=2020. Are BCG-induced non-specific effects adequate to provide protection against COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32845742|t=2020. Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32883116|t=2020. Future perspective: biologic agents in patients with severe COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32871847|t=2020. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.|pdf=|usr=018}}
| |
| − | {{tp|p=32871846|t=2020. Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2.|pdf=|usr=018}}
| |
| − | {{tp|p=32801224|t=2020. Optimal dosing & time: Issues to get hydroxychloroquine safety & efficacy against COVID-19/SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32644027|t=2020. Tocilizumab for COVID-19: a real 'miracle drug'?|pdf=|usr=018}}
| |
| − | {{tp|p=32866084|t=2020. Preliminary study on relationships among nutritional risk, serum prealbumin, and peripheral blood T cell subsets in patients with severe COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32789663|t=2020. Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32718300|t=2020. In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases.|pdf=|usr=018}}
| |
| − | {{tp|p=32696730|t=2020. Newly Emergent 2019-nCoV and New Uses of an Old Medicine, Doxycycline; A Hypothesis.|pdf=|usr=018}}
| |
| − | {{tp|p=32758675|t=2020. Immunoinformatic construction of an adenovirus-based modular vaccine platform and its application in the design of a SARS-CoV-2 vaccine.|pdf=|usr=018}}
| |
| − | {{tp|p=32862840|t=2020. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.|pdf=|usr=018}}
| |
| − | {{tp|p=32729823|t=2020. Drug evaluation and pharmaceutical care in a critically ill COVID-19 patient.|pdf=|usr=018}}
| |
| − | {{tp|p=32787470|t=2020. Probiotics and Covid-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32886632|t=2020. Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32718410|t=2020. Bacille Calmette-Guerin (BCG) vaccine and the COVID-19 pandemic: responsible stewardship is needed.|pdf=|usr=018}}
| |
| − | {{tp|p=32744166|t=2020. Is vitamin C an effective agent for the prevention of COVID-19 and treatment of severe infection in the ICU?|pdf=|usr=018}}
| |
| − | {{tp|p=32811354|t=2020. Vitamin D can be effective on the prevention of COVID-19 complications: A narrative review on molecular aspects.|pdf=|usr=018}}
| |
| − | {{tp|p=32740371|t=2020. Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32870735|t=2020. Vitamin D in Prevention and Treatment of COVID-19: Current Perspective and Future Prospects.|pdf=|usr=018}}
| |
| − | {{tp|p=32795138|t=2020. Vitamin D and Wellbeing beyond Infections: COVID-19 and Future Pandemics.|pdf=|usr=018}}
| |
| − | {{tp|p=32722759|t=2020. Value of Tenets of Osteopathic Medicine for Patients During COVID-19 Crisis.|pdf=|usr=018}}
| |
| − | {{tp|p=32776139|t=2020. Osteopathic Considerations for the Pregnant Patient with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32888000|t=2020. Comment on: Favipiravir, an antiviral for COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32812051|t=2020. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32610879|t=2020. Hydroxychloroquine for COVID-19: What is our Current State of Knowledge?|pdf=|usr=018}}
| |
| − | {{tp|p=32610873|t=2020. Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.|pdf=|usr=018}}
| |
| − | {{tp|p=32610872|t=2020. Research and Ethics during the COVID-19 Pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32738852|t=2020. Hydroxychloroquin for COVID-19 Why was so much hype?|pdf=|usr=018}}
| |
| − | {{tp|p=32727845|t=2020. Identification of an anti-SARS-CoV-2 receptor-binding domain-directed human monoclonal antibody from a naive semisynthetic library.|pdf=|usr=018}}
| |
| − | {{tp|p=32885740|t=2020. Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an in silico assisted drug-repurposing study.|pdf=|usr=018}}
| |
| − | {{tp|p=32876538|t=2020. Pharmacoinformatics and hypothetical studies on allicin, curcumin, and gingerol as potential candidates against COVID-19-associated proteases.|pdf=|usr=018}}
| |
| − | {{tp|p=32875950|t=2020. Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL(pro) of novel coronavirus SARS-CoV-2 identified using docking and molecular dynamics.|pdf=|usr=018}}
| |
| − | {{tp|p=32873185|t=2020. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M(pro).|pdf=|usr=018}}
| |
| − | {{tp|p=32873176|t=2020. Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses.|pdf=|usr=018}}
| |
| − | {{tp|p=32734828|t=2020. Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular docking and MM-PBSA calculations.|pdf=|usr=018}}
| |
| − | {{tp|p=32729392|t=2020. Antiviral potential of some novel structural analogs of standard drugs repurposed for the treatment of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32762537|t=2020. In silico virtual screening, characterization, docking and molecular dynamics studies of crucial SARS-CoV-2 proteins.|pdf=|usr=018}}
| |
| − | {{tp|p=32762511|t=2020. In silico investigation of phytoconstituents from Indian medicinal herb 'Tinospora cordifolia (giloy)' against SARS-CoV-2 (COVID-19) by molecular dynamics approach.|pdf=|usr=018}}
| |
| − | {{tp|p=32762411|t=2020. Identification of polyphenols from Broussonetia papyrifera as SARS CoV-2 main protease inhibitors using in silico docking and molecular dynamics simulation approaches.|pdf=|usr=018}}
| |
| − | {{tp|p=32752951|t=2020. Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2.|pdf=|usr=018}}
| |
| − | {{tp|p=32752947|t=2020. Predictive modeling by deep learning, virtual screening and molecular dynamics study of natural compounds against SARS-CoV-2 main protease.|pdf=|usr=018}}
| |
| − | {{tp|p=32752944|t=2020. Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32752938|t=2020. In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32741322|t=2020. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.|pdf=|usr=018}}
| |
| − | {{tp|p=32741312|t=2020. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32741259|t=2020. Identification of potential anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics simulation studies.|pdf=|usr=018}}
| |
| − | {{tp|p=32851919|t=2020. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) - a molecular docking study.|pdf=|usr=018}}
| |
| − | {{tp|p=32851912|t=2020. In silico screening of hundred phytocompounds of ten medicinal plants as potential inhibitors of nucleocapsid phosphoprotein of COVID-19: an approach to prevent virus assembly.|pdf=|usr=018}}
| |
| − | {{tp|p=32838660|t=2020. Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2.|pdf=|usr=018}}
| |
| − | {{tp|p=32835632|t=2020. In silico validation of coumarin derivatives as potential inhibitors against Main Protease, NSP10/NSP16-Methyltransferase, Phosphatase and Endoribonuclease of SARS CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32815796|t=2020. Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32815481|t=2020. Molecular docking and simulation studies on SARS-CoV-2 M(pro) reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32811367|t=2020. An in-silico evaluation of dietary components for structural inhibition of SARS-Cov-2 main protease.|pdf=|usr=018}}
| |
| − | {{tp|p=32799761|t=2020. In silico molecular investigations of pyridine N-Oxide compounds as potential inhibitors of SARS-CoV-2: 3D QSAR, molecular docking modeling, and ADMET screening.|pdf=|usr=018}}
| |
| − | {{tp|p=32795148|t=2020. Protein reliability analysis and virtual screening of natural inhibitors for SARS-CoV-2 main protease (M(pro)) through docking, molecular mechanic & dynamic, and ADMET profiling.|pdf=|usr=018}}
| |
| − | {{tp|p=32783586|t=2020. New anti-viral drugs for the treatment of COVID-19 instead of favipiravir.|pdf=|usr=018}}
| |
| − | {{tp|p=32772895|t=2020. Structural insight to hydroxychloroquine-3C-like proteinase complexation from SARS-CoV-2: inhibitor modelling study through molecular docking and MD-simulation study.|pdf=|usr=018}}
| |
| − | {{tp|p=32772892|t=2020. In silico designing of multi-epitope vaccine construct against human coronavirus infections.|pdf=|usr=018}}
| |
| − | {{tp|p=32740262|t=2020. Understanding COVID-19 Vaccines and Their Development.|pdf=|usr=018}}
| |
| − | {{tp|p=32870576|t=2020. QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insights.|pdf=|usr=018}}
| |
| − | {{tp|p=32864768|t=2020. Reply to: "QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insights".|pdf=|usr=018}}
| |
| − | {{tp|p=32740445|t=2020. An expression of concern on research during the Covid-19 pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32740441|t=2020. Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemia.|pdf=|usr=018}}
| |
| − | {{tp|p=32858645|t=2020. Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog.|pdf=|usr=018}}
| |
| − | {{tp|p=32785687|t=2020. Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality.|pdf=|usr=018}}
| |
| − | {{tp|p=32794180|t=2020. IL-18 and infections: Is there a role for targeted therapies?|pdf=|usr=018}}
| |
| − | {{tp|p=32853525|t=2020. Impact of Early Pandemic Stage Mutations on Molecular Dynamics of SARS-CoV-2 M(pro).|pdf=|usr=018}}
| |
| − | {{tp|p=32233478|t=2020. Cov_FB3D: A De Novo Covalent Drug Design Protocol Integrating the BA-SAMP Strategy and Machine-Learning-Based Synthetic Tractability Evaluation.|pdf=|usr=018}}
| |
| − | {{tp|p=32875601|t=2020. Therapeutic plasma exchange in a critically ill Covid-19 patient.|pdf=|usr=018}}
| |
| − | {{tp|p=32833728|t=2020. Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis.|pdf=|usr=018}}
| |
| − |
| |
| − | {{tp|p=31776599|t=2020. Entwicklung von Impfstoffen gegen neu auftretende Infektionskrankheiten mit epidemischem Potenzial.|pdf=|usr=018}}
| |
| − | {{tp|p=32844112|t=2020. Low level laser therapy as a modality to attenuate cytokine storm at multiple levels, enhance recovery, and reduce the use of ventilators in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32805774|t=2020. RNA-dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32686633|t=2020. QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019.|pdf=|usr=018}}
| |
| − | {{tp|p=32870433|t=2020. Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32734502|t=2020. Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report.|pdf=|usr=018}}
| |
| − | {{tp|p=32802540|t=2020. Oral Corticosteroid Relieves Post-COVID-19 Anosmia in a 35-Year-Old Patient.|pdf=|usr=018}}
| |
| − | {{tp|p=32835086|t=2020. Effect of oral l-Glutamine supplementation on Covid-19 treatment.|pdf=|usr=018}}
| |
| − | {{tp|p=32829986|t=2020. Personal View: Low-Dose Lung Radiotherapy Should be Evaluated as a Treatment for Severe COVID-19 Lung Disease.|pdf=|usr=018}}
| |
| − | {{tp|p=32876748|t=2020. A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32725382|t=2020. Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents.|pdf=|usr=018}}
| |
| − | {{tp|p=32856282|t=2020. Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6.|pdf=|usr=018}}
| |
| − | {{tp|p=32767755|t=2020. Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32804426|t=2020. Possible Role of ABCB1 in Lysosomal Accumulation of Azithromycin in COVID-19 Therapy.|pdf=|usr=018}}
| |
| − | {{tp|p=32702224|t=2020. Clozapine in the Time of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32728438|t=2020. Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019.|pdf=|usr=018}}
| |
| − | {{tp|p=32799423|t=2020. Effect of Common Medications on the Expression of SARS-CoV-2 Entry Receptors in Kidney Tissue.|pdf=|usr=018}}
| |
| − | {{tp|p=32876108|t=2020. The influence of bitter-taste receptor (TAS2R) expression in pharmacological response to Chloroquine in obese patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32828069|t=2020. Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein.|pdf=|usr=018}}
| |
| − | {{tp|p=32828990|t=2020. The use of knowledge management tools in viroinformatics. Example study of a highly conserved sequence motif in Nsp3 of SARS-CoV-2 as a therapeutic target.|pdf=|usr=018}}
| |
| − | {{tp|p=32868983|t=2020. Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32654163|t=2020. First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test.|pdf=|usr=018}}
| |
| − | {{tp|p=32887650|t=2020. Treatment with angiotensin II in COVID-19 patients may not be beneficial.|pdf=|usr=018}}
| |
| − | {{tp|p=32718345|t=2020. Inhibiting IL-6 in COVID-19: we are not sure.|pdf=|usr=018}}
| |
| − | {{tp|p=32771054|t=2020. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study.|pdf=|usr=018}}
| |
| − | {{tp|p=32753056|t=2020. Plasma exchange in critically ill COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32859243|t=2020. Ketanserin as potential additive drug to improve V/Q mismatch in COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32859242|t=2020. Convalescent plasma for COVID-19: the risk of pulmonary embolism should not be underestimated!|pdf=|usr=018}}
| |
| − | {{tp|p=32854738|t=2020. Efficacy of tocilizumab treatment in severely ill COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32847620|t=2020. Vitamin C levels in patients with SARS-CoV-2-associated acute respiratory distress syndrome.|pdf=|usr=018}}
| |
| − | {{tp|p=32819415|t=2020. Extracorporeal cytokine adsorption as an alternative to pharmacological inhibition of IL-6 in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32811550|t=2020. Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors.|pdf=|usr=018}}
| |
| − | {{tp|p=32807220|t=2020. Inhaled nitric oxide in patients admitted to intensive care unit with COVID-19 pneumonia.|pdf=|usr=018}}
| |
| − | {{tp|p=32792018|t=2020. High-dose intravenous vitamin C may help in cytokine storm in severe SARS-CoV-2 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32787901|t=2020. Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32671349|t=2020. Evidence of Steroids in Patients With Acute Respiratory Distress Syndrome in Coronavirus Disease 2019.|pdf=|usr=018}}
| |
| − | {{tp|p=32832913|t=2020. Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019.|pdf=|usr=018}}
| |
| − | {{tp|p=32766569|t=2020. Treatment for Severe Coronavirus Disease 2019 With the Seraph-100 Microbind Affinity Blood Filter.|pdf=|usr=018}}
| |
| − | {{tp|p=32804792|t=2020. Core Outcomes Set for Trials in People With Coronavirus Disease 2019.|pdf=|usr=018}}
| |
| − | {{tp|p=32804789|t=2020. International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019.|pdf=|usr=018}}
| |
| − | {{tp|p=32754408|t=2020. The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts.|pdf=|usr=018}}
| |
| − | {{tp|p=32754388|t=2020. Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts.|pdf=|usr=018}}
| |
| − | {{tp|p=32699671|t=2020. Debunking Cannabidiol as a Treatment for COVID-19: Time for the FDA to Adopt a Focused Deterrence Model?|pdf=|usr=018}}
| |
| − | {{tp|p=32685300|t=2020. The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series.|pdf=|usr=018}}
| |
| − | {{tp|p=32818119|t=2020. Early Use of Tocilizumab May Prevent Clinical Deterioration in Select COVID-19 Patients: A Case Series.|pdf=|usr=018}}
| |
| − | {{tp|p=32789088|t=2020. Cardiovascular Considerations of Experimental Hydroxychloroquine Therapy on Patients Diagnosed With COVID-19: A Case Series Review.|pdf=|usr=018}}
| |
| − | {{tp|p=32802622|t=2020. Clinical Outcomes of Early Treatment With Doxycycline for 89 High-Risk COVID-19 Patients in Long-Term Care Facilities in New York.|pdf=|usr=018}}
| |
| − | {{tp|p=32823144|t=2020. The host targeting effect of chloroquine in malaria.|pdf=|usr=018}}
| |
| − | {{tp|p=32837854|t=2020. Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update.|pdf=|usr=018}}
| |
| − | {{tp|p=32837853|t=2020. Colchicine in COVID-19: an Old Drug, New Use.|pdf=|usr=018}}
| |
| − | {{tp|p=32864299|t=2020. Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32863400|t=2020. Nigella sativa L as a potential phytotherapy for coronavirus disease 2019: A mini review of in silico studies.|pdf=|usr=018}}
| |
| − | {{tp|p=32822911|t=2020. A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases.|pdf=|usr=018}}
| |
| − | {{tp|p=32882269|t=2020. Nanotheranostics against COVID-19: From multivalent to immune-targeted materials.|pdf=|usr=018}}
| |
| − | {{tp|p=32746637|t=2020. Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro.|pdf=|usr=018}}
| |
| − | {{tp|p=32888840|t=2020. Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics.|pdf=|usr=018}}
| |
| − | {{tp|p=32888976|t=2020. Early short-course corticosteroids and furosemide combination to treat non-critically ill COVID-19 patients: An observational cohort study.|pdf=|usr=018}}
| |
| − | {{tp|p=32844224|t=2020. Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32889701|t=2020. Drug repurposing approach to fight COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32764148|t=2020. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32860252|t=2020. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32723468|t=2020. Convalescent Plasma: Promise for COVID-19 Pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32723461|t=2020. Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.|pdf=|usr=018}}
| |
| − | {{tp|p=32763058|t=2020. Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study.|pdf=|usr=018}}
| |
| − | {{tp|p=32875925|t=2020. Active-site Molecular docking of Nigellidine with nucleocapsid- NSP2-MPro of COVID-19 and to human IL1R-IL6R and strong antioxidant role of Nigella-sativa in experimental rats.|pdf=|usr=018}}
| |
| − | {{tp|p=32870539|t=2020. Generalized pustular figurate erythema first report in two COVID-19 patients on hydroxychloroquine.|pdf=|usr=018}}
| |
| − | {{tp|p=32821033|t=2020. SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32804611|t=2020. Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32887991|t=2020. Immunosenescence and SARS-CoV-2 Vaccine Development.|pdf=|usr=018}}
| |
| − | {{tp|p=32845317|t=2020. Large Simple Double-Blind Randomized Trials for the Rapid Assessment of the Effectiveness of COVID-19 Vaccines.|pdf=|usr=018}}
| |
| − | {{tp|p=32845303|t=2020. Human Challenge Studies Are Unlikely to Accelerate Coronavirus Vaccine Licensure Due to Ethical and Practical Issues.|pdf=|usr=018}}
| |
| − | {{tp|p=32792254|t=2020. Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32881593|t=2020. Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.|pdf=|usr=018}}
| |
| − | {{tp|p=32790488|t=2020. A Geroscience Approach to Preventing Pathologic Consequences of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32845145|t=2020. Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).|pdf=|usr=018}}
| |
| − | {{tp|p=32816615|t=2020. Could Sumac Be Effective on COVID-19 Treatment?|pdf=|usr=018}}
| |
| − | {{tp|p=32886358|t=2020. Tolerability of Favipiravir therapy in critically-ill patients with COVID-19: a report of 4 cases.|pdf=|usr=018}}
| |
| − | {{tp|p=32881014|t=2020. Short-term inhibition of SARS-CoV-2 by hydrogen peroxide in persistent nasopharyngeal carriers.|pdf=|usr=018}}
| |
| − | {{tp|p=32881007|t=2020. Are the steroids a blanket solution for COVID-19? a systematic review and meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32729947|t=2020. Could an acute respiratory distress syndrome in COVID-19 infected patients be calmed down simply by iron withdrawal from lung tissues?|pdf=|usr=018}}
| |
| − | {{tp|p=32860432|t=2020. Tocilizumab use in COVID -19 associated pneumonia.|pdf=|usr=018}}
| |
| − | {{tp|p=32860431|t=2020. Evaluation of seventeen patients with COVID-19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA and Brescia-COVID respiratory severity scale (BCRSS) scoring systems.|pdf=|usr=018}}
| |
| − | {{tp|p=32711596|t=2020. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.|pdf=|usr=018}}
| |
| − | {{tp|p=32504017|t=2020. India expands use of controversial drug for coronavirus despite safety concerns.|pdf=|usr=018}}
| |
| − | {{tp|p=32731258|t=2020. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.|pdf=|usr=018}}
| |
| − | {{tp|p=32731257|t=2020. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.|pdf=|usr=018}}
| |
| − | {{tp|p=32726802|t=2020. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.|pdf=|usr=018}}
| |
| − | {{tp|p=32756549|t=2020. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.|pdf=|usr=018}}
| |
| − | {{tp|p=32785213|t=2020. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults.|pdf=|usr=018}}
| |
| − | {{tp|p=32820261|t=2020. Evidence lags behind excitement over blood plasma as a coronavirus treatment.|pdf=|usr=018}}
| |
| − | {{tp|p=32812005|t=2020. How we accelerated clinical trials in the age of coronavirus.|pdf=|usr=018}}
| |
| − | {{tp|p=32782400|t=2020. Russia's fast-track coronavirus vaccine draws outrage over safety.|pdf=|usr=018}}
| |
| − | {{tp|p=32698192|t=2020. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.|pdf=|usr=018}}
| |
| − | {{tp|p=32749808|t=2020. Hydroxychloroquine en chloroquine bij COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32839298|t=2020. Editors' note: Miller Fisher syndrome and polyneuritis cranialis in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32796470|t=2020. A theranostic approach based on radiolabeled antiviral drugs, antibodies and CRISPR-associated proteins for early detection and treatment of SARS-CoV-2 disease.|pdf=|usr=018}}
| |
| − | {{tp|p=32738510|t=2020. Parenteral fish oil: An adjuvant pharmacotherapy for coronavirus disease 2019?|pdf=|usr=018}}
| |
| − | {{tp|p=32769659|t=2020. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).|pdf=|usr=018}}
| |
| − | {{tp|p=32852324|t=2020. High Concentrations of Nitric Oxide Inhalation Therapy in Pregnant Patients With Severe Coronavirus Disease 2019 (COVID-19).|pdf=|usr=018}}
| |
| − | {{tp|p=32757981|t=2020. In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32857671|t=2020. Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine.|pdf=|usr=018}}
| |
| − | {{tp|p=32833598|t=2020. Turning Up the Volume for Precision Herbal Medicine in Africa in an Era of COVID-19 and Planetary Biodiversity Loss.|pdf=|usr=018}}
| |
| − | {{tp|p=32885904|t=2020. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.|pdf=|usr=018}}
| |
| − | {{tp|p=32814341|t=2020. COVID-19 and remdesivir in pediatric patients: the invisible part of the iceberg.|pdf=|usr=018}}
| |
| − | {{tp|p=32758635|t=2020. COVID-19: Pharmacology and kinetics of viral clearance.|pdf=|usr=018}}
| |
| − | {{tp|p=32758336|t=2020. Avoiding COVID-19 complications with diabetic patients could be achieved by multi-dose Bacillus Calmette-Guerin vaccine: a case study of beta cells regeneration.|pdf=|usr=018}}
| |
| − | {{tp|p=32800699|t=2020. The add-on effect of Chinese herbal medicine on COVID-19: A systematic review and meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32248575|t=2020. Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data.|pdf=|usr=018}}
| |
| − | {{tp|p=32820084|t=2020. COVID-19 and the burning issue of drug interaction: never forget the ECG.|pdf=|usr=018}}
| |
| − | {{tp|p=32817576|t=2020. Risk-benefit analysis on the clinical significance of convalescent plasma therapy in the management of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32788309|t=2020. Chloroquine and hydroxychloroquine for COVID-19: time to close the chapter.|pdf=|usr=018}}
| |
| − | {{tp|p=32868447|t=2020. A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants.|pdf=|usr=018}}
| |
| − |
| |
| − | {{tp|p=32734518|t=2020. Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32857301|t=2020. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.|pdf=|usr=018}}
| |
| − | {{tp|p=32812187|t=2020. Is there any potential management against COVID-19? A systematic review and meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32803688|t=2020. The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32772478|t=2020. Androgen sensitivity in COVID-19 and antiandrogens: Prospective data are still needed.|pdf=|usr=018}}
| |
| − | {{tp|p=32740972|t=2020. Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes.|pdf=|usr=018}}
| |
| − | {{tp|p=32750451|t=2020. Metformin and COVID-19: From cellular mechanisms to reduced mortality.|pdf=|usr=018}}
| |
| − | {{tp|p=32755836|t=2020. Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges.|pdf=|usr=018}}
| |
| − | {{tp|p=32868092|t=2020. COVID-19: Therapeutics and interventions currently under consideration.|pdf=|usr=018}}
| |
| − | {{tp|p=32868978|t=2020. Unethical not to Investigate Radiotherapy for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32855629|t=2020. Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China.|pdf=|usr=018}}
| |
| − | {{tp|p=32748035|t=2020. Nanotechnology-based antiviral therapeutics.|pdf=|usr=018}}
| |
| − | {{tp|p=32821086|t=2020. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32801640|t=2020. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32753842|t=2020. Plasmapheresis, Anti-ACE2 and Anti-FcgammaRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32779824|t=2020. Volatile molecules for COVID-19: A possible pharmacological strategy?|pdf=|usr=018}}
| |
| − | {{tp|p=32770567|t=2020. Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.|pdf=|usr=018}}
| |
| − | {{tp|p=32761647|t=2020. Snake venom-derived bradykinin-potentiating peptides: A promising therapy for COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32669523|t=2020. Traditional Chinese medicine to treat COVID-19: the importance of evidence-based research.|pdf=|usr=018}}
| |
| − | {{tp|p=32669519|t=2020. Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies.|pdf=|usr=018}}
| |
| − | {{tp|p=32777537|t=2020. Global clinical trial mobilization for COVID-19: higher, faster, stronger.|pdf=|usr=018}}
| |
| − | {{tp|p=32801052|t=2020. Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites.|pdf=|usr=018}}
| |
| − | {{tp|p=32006468|t=2020. Recent discovery and development of inhibitors targeting coronaviruses.|pdf=|usr=018}}
| |
| − | {{tp|p=32443163|t=2020. Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta.|pdf=|usr=018}}
| |
| − | {{tp|p=32870481|t=2020. Remdesivir: First Approval.|pdf=|usr=018}}
| |
| − | {{tp|p=32742294|t=2020. Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus.|pdf=|usr=018}}
| |
| − | {{tp|p=32853989|t=2020. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32807701|t=2020. Immunodominant epitopes based serological assay for detecting SARS-CoV-2 exposure: Promises and challenges.|pdf=|usr=018}}
| |
| − | {{tp|p=32766547|t=2020. A vaccine for SARS-CoV-2: goals and promises.|pdf=|usr=018}}
| |
| − | {{tp|p=32838238|t=2020. A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-kappa plus TFF2 in patients with moderate COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32838235|t=2020. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up.|pdf=|usr=018}}
| |
| − | {{tp|p=32876089|t=2020. Mesenchymal stem cells in the treatment of coronavirus-induced pneumonia (COVID-19).|pdf=|usr=018}}
| |
| − | {{tp|p=32845033|t=2020. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32753375|t=2020. BET 1: The role of remdesivir in COVID-19 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32795143|t=2020. Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study.|pdf=|usr=018}}
| |
| − | {{tp|p=29907366|t=2019. Uso de ribavirina en virus distintos de la hepatitis C. Una revision de la evidencia.|pdf=|usr=018}}
| |
| − | {{tp|p=32875809|t=2020. Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5'UTR of SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32379307|t=2020. Statin therapy and SAR-COV-2: an available and potential therapy?|pdf=|usr=018}}
| |
| − | {{tp|p=32885275|t=2020. Molecular mechanisms involved in the positive effects of physical activity on coping with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32735689|t=2020. Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32810285|t=2020. Efficacy of various treatment modalities for nCOV-2019: A systematic review and meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32856202|t=2020. A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.|pdf=|usr=018}}
| |
| − | {{tp|p=32870381|t=2020. Reply: Iron chelation may harm patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32870380|t=2020. Re-recognizing bromhexine hydrochloride: pharmaceutical properties and its possible role in treating pediatric COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32870379|t=2020. Iron chelation may harm patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32780229|t=2020. Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32780273|t=2020. Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention.|pdf=|usr=018}}
| |
| − | {{tp|p=32501408|t=2020. Can network pharmacology identify the anti-virus and anti- inflammatory activities of Shuanghuanglian oral liquid used in Chinese medicine for respiratory tract infection?|pdf=|usr=018}}
| |
| − | {{tp|p=32819797|t=2020. Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out.|pdf=|usr=018}}
| |
| − | {{tp|p=32859477|t=2020. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.|pdf=|usr=018}}
| |
| − | {{tp|p=32771797|t=2020. Potential treatment methods targeting 2019-nCoV infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32810751|t=2020. The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020.|pdf=|usr=018}}
| |
| − | {{tp|p=32871342|t=2020. Azithromycin: The First Broad-spectrum Therapeutic.|pdf=|usr=018}}
| |
| − | {{tp|p=32798789|t=2020. Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds.|pdf=|usr=018}}
| |
| − | {{tp|p=32854774|t=2020. How to follow-up a patient who received tocilizumab in severe COVID-19: a case report.|pdf=|usr=018}}
| |
| − | {{tp|p=32851419|t=2020. Vitamin D and COVID-19 infection and mortality in UK Biobank.|pdf=|usr=018}}
| |
| − | {{tp|p=32730844|t=2020. Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages.|pdf=|usr=018}}
| |
| − | {{tp|p=32827661|t=2020. Emerging strategies on in silico drug development against COVID-19: challenges and opportunities.|pdf=|usr=018}}
| |
| − | {{tp|p=32777212|t=2020. What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results.|pdf=|usr=018}}
| |
| − | {{tp|p=32768505|t=2020. COVID-19: A review of the proposed pharmacological treatments.|pdf=|usr=018}}
| |
| − | {{tp|p=32768503|t=2020. In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32763302|t=2020. Coronavirus diseases 2019: Current biological situation and potential therapeutic perspective.|pdf=|usr=018}}
| |
| − | {{tp|p=32763298|t=2020. Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations.|pdf=|usr=018}}
| |
| − | {{tp|p=32758569|t=2020. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32841640|t=2020. Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32841639|t=2020. Food proteins are a potential resource for mining cathepsin L inhibitory drugs to combat SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32828741|t=2020. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial.|pdf=|usr=018}}
| |
| − | {{tp|p=32750366|t=2020. An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment.|pdf=|usr=018}}
| |
| − | {{tp|p=32802131|t=2020. Network Pharmacology Integrated Molecular Docking Reveals the Mechanism of Anisodamine Hydrobromide Injection against Novel Coronavirus Pneumonia.|pdf=|usr=018}}
| |
| − | {{tp|p=32845978|t=2020. Investigating Low-Dose Thoracic Radiation as a Treatment for COVID-19 Patients to Prevent Respiratory Failure.|pdf=|usr=018}}
| |
| − | {{tp|p=32814539|t=2020. Is ocular toxicity expected in chloroquine/hydroxychloroquine prescription as a therapeutic or prophylactic option in COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32319447|t=2020. Viramina D e coronavirus: un nuovo campo di impiego?|pdf=|usr=018}}
| |
| − | {{tp|p=32856339|t=2020. Vitamin D and Covid-19: From potential therapeutic effects to unanswered questions.|pdf=|usr=018}}
| |
| − | {{tp|p=32876224|t=2020. Agentes potencialmente terapeuticos contra el SARS-CoV-2: revision rapida de la evidencia.|pdf=|usr=018}}
| |
| − | {{tp|p=32880317|t=2020. COVID-19: Convalescent plasma as a potential therapy.|pdf=|usr=018}}
| |
| − | {{tp|p=32880303|t=2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32657706|t=2020. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.|pdf=|usr=018}}
| |
| − | {{tp|p=32847369|t=2020. Extending the identification of structural features responsible for anti-SARS-CoV activity of peptide-type compounds using QSAR modelling.|pdf=|usr=018}}
| |
| − | {{tp|p=32875611|t=2020. SARS-CoV-2 And Trojan Horse Phenomenon -Caveat In Vaccine Quest?|pdf=|usr=018}}
| |
| − | {{tp|p=32747425|t=2020. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.|pdf=|usr=018}}
| |
| − | {{tp|p=32883851|t=2020. A molecular trap against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32732280|t=2020. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy.|pdf=|usr=018}}
| |
| − | {{tp|p=32631874|t=2020. The line starts to form for a coronavirus vaccine.|pdf=|usr=018}}
| |
| − | {{tp|p=32739134|t=2020. Tratamiento farmacologico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32790618|t=2020. Drugs Repositioned for COVID-19 Are Routinely Prescribed by Dermatologists.|pdf=|usr=018}}
| |
| − | {{tp|p=32692266|t=2020. Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.|pdf=|usr=018}}
| |
| − | {{tp|p=32804597|t=2020. Based on Principles and Insights of COVID-19 Epidemiology, Genome Sequencing, and Pathogenesis: Retrospective Analysis of Sinigrin and Prolixin(RX) (Fluphenazine) Provides Off-Label Drug Candidates.|pdf=|usr=018}}
| |
| − | {{tp|p=32710694|t=2020. Potential limitations of plasmapheresis in treatment of COVID-19 patients: How to overcome them?|pdf=|usr=018}}
| |
| − | {{tp|p=32757745|t=2020. Gold nanoparticles against respiratory diseases: oncogenic and viral pathogens review.|pdf=|usr=018}}
| |
| − | {{tp|p=32829936|t=2020. Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32773244|t=2020. Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines.|pdf=|usr=018}}
| |
| − | {{tp|p=32684497|t=2020. Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus.|pdf=|usr=018}}
| |
| − | {{tp|p=32448096|t=2020. Immunization with porcine epidemic diarrhea virus harbouring Fc domain of IgG enhances antibody production in pigs.|pdf=|usr=018}}
| |
| − | {{tp|p=32857679|t=2020. Is There a Rationale for Using Bacillus Calmette-Guerin Vaccine in Coronavirus Infection?|pdf=|usr=018}}
| |
| − | {{tp|p=32759459|t=2020. Hydroxychloroquine is no miracle cure for covid-19 infection -imaging and clinical course in an elderly female.|pdf=|usr=018}}
| |
| − | {{tp|p=32696759|t=2020. [Discussion and prospect of infusion of NK cells in the treatment of SARS-CoV-2 infection].|pdf=|usr=018}}
| |
| − | {{tp|p=32762168|t=2020. [Nutritional support for critically ill patients with COVID-19].|pdf=|usr=018}}
| |
| − | {{tp|p=32648389|t=2020. [Exploration of fire needling therapy on coronavirus disease 2019].|pdf=|usr=018}}
| |
| − | {{tp|p=32869585|t=2020. [Discussion on the effect pathways of preventing and treating coronavirus disease 2019 by acupuncture and moxibustion from the regulation of immune inflammatory response].|pdf=|usr=018}}
| |
| − | {{tp|p=32726008|t=2020. [Analysis of potential role of Chinese classic prescriptions in treatment of COVID-19 based on TCMATCOV platform].|pdf=|usr=018}}
| |
| − | {{tp|p=32726007|t=2020. [Study on therapeutic effect of Chaiyin Particles on combining disease with syndrome of human coronavirus pneumonia with pestilence attacking lung syndrome based on regulation of immune function].|pdf=|usr=018}}
| |
| − | {{tp|p=32726006|t=2020. [Analysis on formula of Mongolian medicine for prevention of COVID-19].|pdf=|usr=018}}
| |
| − | {{tp|p=32726005|t=2020. [Analysis of medication regularity and pharmacodynamic characteristics of traditional Chinese medicine treatment in 444 severe cases of COVID-19].|pdf=|usr=018}}
| |
| − | {{tp|p=32726004|t=2020. [Analysis of traditional Chinese medicine from patent information sharing platform of coronavirus disease 2019 (COVID-19)].|pdf=|usr=018}}
| |
| − | {{tp|p=32726003|t=2020. [Large- scale prospective clinical study on prophylactic intervention of COVID-19 in community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules].|pdf=|usr=018}}
| |
| − | {{tp|p=32489026|t=2020. [Intervention mechanism of Qingwen Baidu Yin on cytokine storm based on network pharmacology].|pdf=|usr=018}}
| |
| − | {{tp|p=32385989|t=2020. [Glucocorticoid for coronavirus disease 2019: a dilemma].|pdf=|usr=018}}
| |
| − | {{tp|p=32684211|t=2020. [A comparative study on clinical effects of dexmedetomidine and midazolam on patients with severe coronavirus disease 2019 on non-invasive ventilation].|pdf=|usr=018}}
| |
| − | {{tp|p=32684209|t=2020. [Meta-analysis of single-group rate of the distribution of traditional Chinese medicine syndromes in 2 139 patients with coronavirus disease 2019].|pdf=|usr=018}}
| |
| − | {{tp|p=32684207|t=2020. [Exploration on the therapeutic mechanisms and safety of blood components of convalescents without erythrocytes on severe acute respiratory syndrome and coronavirus disease 2019].|pdf=|usr=018}}
| |
| − | {{tp|p=32684206|t=2020. [Application of convalescent plasma for the treatment of adult patients with coronavirus disease 2019].|pdf=|usr=018}}
| |
| − | {{tp|p=32684205|t=2020. [Expert opinion on diagnosis and treatment of coronavirus disease 2019 with traditional Chinese medicine based on "three syndromes and three methods"].|pdf=|usr=018}}
| |
| − |
| |
| − | {{tp|p=32779213|t=2020. COVID-19 and Vitamin D: A lesson from the skin.|pdf=|usr=018}}
| |
| − | {{tp|p=32782493|t=2020. Repurposing current therapeutic regimens against SARS-CoV-2 (Review).|pdf=|usr=018}}
| |
| − | {{tp|p=32783643|t=2020. Host-directed therapies: a potential solution to combat COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32762581|t=2020. Immunotherapy for SARS-CoV-2: potential opportunities.|pdf=|usr=018}}
| |
| − | {{tp|p=32850116|t=2020. Development of vaccines for SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32802318|t=2020. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.|pdf=|usr=018}}
| |
| − | {{tp|p=32765844|t=2020. In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32742639|t=2020. Turning up the heat on COVID-19: heat as a therapeutic intervention.|pdf=|usr=018}}
| |
| − | {{tp|p=32704354|t=2020. Coronavirus disease 2019 drug discovery through molecular docking.|pdf=|usr=018}}
| |
| − | {{tp|p=32704352|t=2020. Recruiting the innate immune system with GM-CSF to fight viral diseases, including West Nile Virus encephalitis and COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32780893|t=2020. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32760352|t=2020. COVID-19 and Diabetes: The Importance of Controlling RAGE.|pdf=|usr=018}}
| |
| − | {{tp|p=32849658|t=2020. Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?|pdf=|usr=018}}
| |
| − | {{tp|p=32849655|t=2020. Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung.|pdf=|usr=018}}
| |
| − | {{tp|p=32849647|t=2020. Can Drinking Microfiltered Raw Immune Milk From Cows Immunized Against SARS-CoV-2 Provide Short-Term Protection Against COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32849643|t=2020. Contriving Multi-Epitope Subunit of Vaccine for COVID-19: Immunoinformatics Approaches.|pdf=|usr=018}}
| |
| − | {{tp|p=32849619|t=2020. Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus.|pdf=|usr=018}}
| |
| − | {{tp|p=32793246|t=2020. Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32793245|t=2020. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.|pdf=|usr=018}}
| |
| − | {{tp|p=32760409|t=2020. Could the Induction of Trained Immunity by beta-Glucan Serve as a Defense Against COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32760408|t=2020. Prevention of Severe Coronavirus Disease 2019 Outcomes by Reducing Low-Grade Inflammation in High-Risk Categories.|pdf=|usr=018}}
| |
| − | {{tp|p=32760407|t=2020. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.|pdf=|usr=018}}
| |
| − | {{tp|p=32754165|t=2020. A Hypothesis for the Possible Role of Zinc in the Immunological Pathways Related to COVID-19 Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32754164|t=2020. The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis.|pdf=|usr=018}}
| |
| − | {{tp|p=32754161|t=2020. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach.|pdf=|usr=018}}
| |
| − | {{tp|p=32754160|t=2020. Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach.|pdf=|usr=018}}
| |
| − | {{tp|p=32733489|t=2020. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.|pdf=|usr=018}}
| |
| − | {{tp|p=32733488|t=2020. Potential Fast COVID-19 Containment With Trehalose.|pdf=|usr=018}}
| |
| − | {{tp|p=32719685|t=2020. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies.|pdf=|usr=018}}
| |
| − | {{tp|p=32719684|t=2020. COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.|pdf=|usr=018}}
| |
| − | {{tp|p=32719683|t=2020. Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment.|pdf=|usr=018}}
| |
| − | {{tp|p=32761491|t=2020. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32850924|t=2020. Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32850922|t=2020. Treatment Options for COVID-19: A Review.|pdf=|usr=018}}
| |
| − | {{tp|p=32850921|t=2020. Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol.|pdf=|usr=018}}
| |
| − | {{tp|p=32850920|t=2020. Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32850918|t=2020. Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32850916|t=2020. Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion.|pdf=|usr=018}}
| |
| − | {{tp|p=32766266|t=2020. Administration of Immunoglobulins in SARS-CoV-2-Positive Patient Is Associated With Fast Clinical and Radiological Healing: Case Report.|pdf=|usr=018}}
| |
| − | {{tp|p=32733907|t=2020. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32714936|t=2020. Aging and Coronavirus: Exploring Complementary Therapies to Avoid Inflammatory Overload.|pdf=|usr=018}}
| |
| − | {{tp|p=32849448|t=2020. Directly Acting Antivirals for COVID-19: Where Do We Stand?|pdf=|usr=018}}
| |
| − | {{tp|p=32793181|t=2020. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32765482|t=2020. Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review.|pdf=|usr=018}}
| |
| − | {{tp|p=32754147|t=2020. Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro.|pdf=|usr=018}}
| |
| − | {{tp|p=32850978|t=2020. Combination Therapy Using Inhalable GapmeR and Recombinant ACE2 for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32850973|t=2020. A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment.|pdf=|usr=018}}
| |
| − | {{tp|p=32850963|t=2020. Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease.|pdf=|usr=018}}
| |
| − | {{tp|p=32850428|t=2020. On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents.|pdf=|usr=018}}
| |
| − | {{tp|p=32848802|t=2020. A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes.|pdf=|usr=018}}
| |
| − | {{tp|p=32848795|t=2020. COVID-19 Therapeutic Options Under Investigation.|pdf=|usr=018}}
| |
| − | {{tp|p=32848790|t=2020. Medicinal Plants as Sources of Active Molecules Against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32848788|t=2020. DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19-A Therapeutic Approach of Choice in Type 2 Diabetic Patients?|pdf=|usr=018}}
| |
| − | {{tp|p=32848776|t=2020. Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention.|pdf=|usr=018}}
| |
| − | {{tp|p=32848774|t=2020. Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use.|pdf=|usr=018}}
| |
| − | {{tp|p=32848769|t=2020. DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?|pdf=|usr=018}}
| |
| − | {{tp|p=32848765|t=2020. Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32848729|t=2020. Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China.|pdf=|usr=018}}
| |
| − | {{tp|p=32792942|t=2020. Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of I K(M) or I K(DR) and in the Stimulation of I MEP.|pdf=|usr=018}}
| |
| − | {{tp|p=32765279|t=2020. Selective Estrogen Receptor Modulators in COVID-19: A Possible Therapeutic Option?|pdf=|usr=018}}
| |
| − | {{tp|p=32765274|t=2020. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.|pdf=|usr=018}}
| |
| − | {{tp|p=32765270|t=2020. The Folate Concentration and/or Folic Acid Metabolites in Plasma as Factor for COVID-19 Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32754036|t=2020. BCG Against SARS-CoV-2: Second Youth of an Old Age Vaccine?|pdf=|usr=018}}
| |
| − | {{tp|p=32574233|t=2020. Small Molecule Inhibitors of CRM1.|pdf=|usr=018}}
| |
| − | {{tp|p=32848845|t=2020. Non-invasive Auricular Vagus Nerve Stimulation as a Potential Treatment for Covid19-Originated Acute Respiratory Distress Syndrome.|pdf=|usr=018}}
| |
| − | {{tp|p=32719619|t=2020. While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?|pdf=|usr=018}}
| |
| − | {{tp|p=32754571|t=2020. Novel Coronavirus Pneumonia Treatment With Traditional Chinese Medicine: Response Philosophy in Another Culture.|pdf=|usr=018}}
| |
| − | {{tp|p=32733842|t=2020. Progress in the Research and Development of Anti-COVID-19 Drugs.|pdf=|usr=018}}
| |
| − | {{tp|p=32733837|t=2020. A Perspective on Emerging Therapeutic Interventions for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32719766|t=2020. Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression.|pdf=|usr=018}}
| |
| − | {{tp|p=32787684|t=2020. Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an in silico repurposing study.|pdf=|usr=018}}
| |
| − | {{tp|p=32845164|t=2020. Phages in the fight against COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32777281|t=2020. What underlies the benefit of famotidine formulations used during COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32877709|t=2020. The New Foe and Old Friends: Are We Ready for Microbiota-based Therapeutics in Treating COVID-19 Patients?|pdf=|usr=018}}
| |
| − | {{tp|p=32875166|t=2020. In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors.|pdf=|usr=018}}
| |
| − | {{tp|p=32884603|t=2020. Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32791978|t=2020. Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes.|pdf=|usr=018}}
| |
| − | {{tp|p=32771622|t=2020. Global multi-omics and systems pharmacological strategy unravel the multi-targeted therapeutic potential of natural bioactive molecules against COVID-19: An in silico approach.|pdf=|usr=018}}
| |
| − | {{tp|p=32733775|t=2020. Ascorbate as Prophylaxis and Therapy for COVID-19-Update From Shanghai and U.S. Medical Institutions.|pdf=|usr=018}}
| |
| − | {{tp|p=32861559|t=2020. Statins in COVID-19: A new ray of hope.|pdf=|usr=018}}
| |
| − | {{tp|p=32754651|t=2020. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study.|pdf=|usr=018}}
| |
| − | {{tp|p=32869005|t=2020. A drug screening toolkit based on the -1 ribosomal frameshifting of SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32802983|t=2020. Study of the structural, chemical descriptors and optoelectronic properties of the drugs Hydroxychloroquine and Azithromycin.|pdf=|usr=018}}
| |
| − | {{tp|p=32802982|t=2020. Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz.|pdf=|usr=018}}
| |
| − | {{tp|p=32802981|t=2020. Searching potential antiviral candidates for the treatment of the 2019 novel coronavirus based on DFT calculations and molecular docking.|pdf=|usr=018}}
| |
| − | {{tp|p=32802980|t=2020. Predicting novel drugs for SARS-CoV-2 using machine learning from a >10 million chemical space.|pdf=|usr=018}}
| |
| − | {{tp|p=32725454|t=2020. Liver injury in remdesivir-treated COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32780299|t=2020. Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective.|pdf=|usr=018}}
| |
| − | {{tp|p=32840387|t=2020. Synthesis of N,N'-bis(1,5-dimethyl-2-phenyl-1,2-dihydro-3-oxopyrazol-4-yl) sebacamide that ameliorate osteoarthritis symptoms and improve bone marrow matrix structure and cartilage alterations induced by monoiodoacetate in the rat model: "Suggested potent anti-inflammatory agent against COVID-19".|pdf=|usr=018}}
| |
| − | {{tp|p=32783919|t=2020. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.|pdf=|usr=018}}
| |
| − | {{tp|p=32681497|t=2020. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.|pdf=|usr=018}}
| |
| − | {{tp|p=32695719|t=2020. Hydroxychloroquine in Dermatology and Beyond: Recent Update.|pdf=|usr=018}}
| |
| − | {{tp|p=32837034|t=2020. Role of Vitamin D Supplementation in Prevention and Treatment of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32837032|t=2020. Curcumin and Coagulopathy in the COVID19 Era.|pdf=|usr=018}}
| |
| − | {{tp|p=32837035|t=2020. Snapshot of COVID-19 Related Clinical Trials in India.|pdf=|usr=018}}
| |
| − | {{tp|p=32719218|t=2020. Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.|pdf=|usr=018}}
| |
| − | {{tp|p=32874008|t=2020. Indian perspective of remdesivir: A promising COVID-19 drug.|pdf=|usr=018}}
| |
| − | {{tp|p=32825892|t=2020. White paper on Ivermectin as a potential therapy for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32757500|t=2020. Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series.|pdf=|usr=018}}
| |
| − | {{tp|p=32757497|t=2020. Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication.|pdf=|usr=018}}
| |
| − | {{tp|p=32869558|t=2020. Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence.|pdf=|usr=018}}
| |
| − | {{tp|p=32835142|t=2020. Will an imperfect vaccine curtail the COVID-19 pandemic in the U.S.?|pdf=|usr=018}}
| |
| − | {{tp|p=32741372|t=2020. Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32880102|t=2020. Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study.|pdf=|usr=018}}
| |
| − | {{tp|p=32740858|t=2020. The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse.|pdf=|usr=018}}
| |
| − | {{tp|p=32745811|t=2020. Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2.|pdf=|usr=018}}
| |
| − | {{tp|p=32791240|t=2020. Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32803479|t=2020. COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties.|pdf=|usr=018}}
| |
| − | {{tp|p=32797326|t=2020. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality.|pdf=|usr=018}}
| |
| − | {{tp|p=32835083|t=2020. Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors.|pdf=|usr=018}}
| |
| − | {{tp|p=32835079|t=2020. A SARS-CoV-2 vaccine candidate: In-silico cloning and validation.|pdf=|usr=018}}
| |
| − | {{tp|p=32774508|t=2020. Chloroquine and COVID-19: Should We Care about Ototoxicity?|pdf=|usr=018}}
| |
| − |
| |
| − | {{tp|p=32795898|t=2020. Oxygen-ozone (O2-O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported.|pdf=|usr=018}}
| |
| − | {{tp|p=32795893|t=2020. Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments.|pdf=|usr=018}}
| |
| − | {{tp|p=32795897|t=2020. Thymosin alpha1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study.|pdf=|usr=018}}
| |
| − | {{tp|p=32862111|t=2020. Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial.|pdf=|usr=018}}
| |
| − | {{tp|p=32862110|t=2020. Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.|pdf=|usr=018}}
| |
| − | {{tp|p=32877828|t=2020. Immunotherapeutic approaches to curtail COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32739476|t=2020. Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?|pdf=|usr=018}}
| |
| − | {{tp|p=32738307|t=2020. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32738306|t=2020. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32738305|t=2020. Lactoferrin as potential preventative and adjunct treatment for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32853675|t=2020. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32853673|t=2020. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants.|pdf=|usr=018}}
| |
| − | {{tp|p=32853672|t=2020. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.|pdf=|usr=018}}
| |
| − | {{tp|p=32777263|t=2020. Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results.|pdf=|usr=018}}
| |
| − | {{tp|p=32745548|t=2020. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.|pdf=|usr=018}}
| |
| − | {{tp|p=32853604|t=2020. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32760915|t=2020. Glucocorticoids save lives in COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32760206|t=2020. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.|pdf=|usr=018}}
| |
| − | {{tp|p=32676542|t=2020. Insights into Potential Mechanisms of Injury and Treatment Targets in COVID-19, SARS-Cov-2 Infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32767379|t=2020. Biologic drugs during COVID-19 outbreak.|pdf=|usr=018}}
| |
| − | {{tp|p=32756371|t=2020. BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study.|pdf=|usr=018}}
| |
| − | {{tp|p=32801840|t=2020. A Review on Currently Available Potential Therapeutic Options for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32799596|t=2020. Could nasal irrigation and oral rinse reduce the risk for COVID-19 infection?|pdf=|usr=018}}
| |
| − | {{tp|p=32745629|t=2020. A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32738491|t=2020. Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?|pdf=|usr=018}}
| |
| − | {{tp|p=32738490|t=2020. The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32738483|t=2020. Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32726724|t=2020. Appropriate use of tocilizumab in COVID-19 infection.|pdf=|usr=018}}
| |
| − | {{tp|p=32721534|t=2020. Adsorptive granulocyte and monocyte apheresis: A potentially relevant therapeutic option for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32721528|t=2020. Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge.|pdf=|usr=018}}
| |
| − | {{tp|p=32771630|t=2020. Comment on Arshad et al.: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32768698|t=2020. Hydroxychloroquine in COVID-19: Taking care of statistics to take care of patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32768697|t=2020. Vitamin D3 and K2 and their potential contribution to reducing the COVID-19 mortality rate.|pdf=|usr=018}}
| |
| − | {{tp|p=32768693|t=2020. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.|pdf=|usr=018}}
| |
| − | {{tp|p=32768701|t=2020. Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation.|pdf=|usr=018}}
| |
| − | {{tp|p=32758689|t=2020. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial.|pdf=|usr=018}}
| |
| − | {{tp|p=32861824|t=2020. The significance of correct dosing of hydroxychloroquine in clinical trials of COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32829047|t=2020. CORTICOSTEROIDS IN THE TREATMENT OF SEVERE COVID-19 LUNG DISEASE: THE PULMONOLOGY PERSPECTIVE FROM THE FIRST UNITED STATES EPICENTER.|pdf=|usr=018}}
| |
| − | {{tp|p=32829044|t=2020. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition.|pdf=|usr=018}}
| |
| − | {{tp|p=32805422|t=2020. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.|pdf=|usr=018}}
| |
| − | {{tp|p=32798660|t=2020. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32795605|t=2020. Nutritional status of patients with coronavirus disease 2019 (COVID-19).|pdf=|usr=018}}
| |
| − | {{tp|p=32752138|t=2020. Tobacco, but Not Nicotine and Flavor-Less Electronic Cigarettes, Induces ACE2 and Immune Dysregulation.|pdf=|usr=018}}
| |
| − | {{tp|p=32731361|t=2020. Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations.|pdf=|usr=018}}
| |
| − | {{tp|p=32727145|t=2020. Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32718020|t=2020. Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.|pdf=|usr=018}}
| |
| − | {{tp|p=32784899|t=2020. SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells.|pdf=|usr=018}}
| |
| − | {{tp|p=32756480|t=2020. COVID-19: The Immune Responses and Clinical Therapy Candidates.|pdf=|usr=018}}
| |
| − | {{tp|p=32872332|t=2020. Delta9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.|pdf=|usr=018}}
| |
| − | {{tp|p=32825444|t=2020. Are Myths and Preconceptions Preventing us from Applying Ionic Liquid Forms of Antiviral Medicines to the Current Health Crisis?|pdf=|usr=018}}
| |
| − | {{tp|p=32824985|t=2020. 4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.|pdf=|usr=018}}
| |
| − | {{tp|p=32824072|t=2020. New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine.|pdf=|usr=018}}
| |
| − | {{tp|p=32823591|t=2020. Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications.|pdf=|usr=018}}
| |
| − | {{tp|p=32881350|t=2020. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32840231|t=2020. Emerging Treatment Options of Regenerative Medicine in Severe Corona Virus/COVID 19 Infections.|pdf=|usr=018}}
| |
| − | {{tp|p=32821175|t=2020. Hemoperfusion as a Supportive Treatment in a COVID-19 Patient with Late Pulmonary Thromboembolism: A Case Report.|pdf=|usr=018}}
| |
| − | {{tp|p=32875426|t=2020. RNA interference as a promising treatment against SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32864332|t=2021. Efficacy and safety of herbal medicine (Lianhuaqingwen) for treating COVID-19: A systematic review and meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32874913|t=2020. Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19:A pilot randomized clinical trial.|pdf=|usr=018}}
| |
| − | {{tp|p=32837904|t=2020. Choose your shortcuts wisely: COVID-19 rapid reviews of traditional, complementary and integrative medicine.|pdf=|usr=018}}
| |
| − | {{tp|p=32834994|t=2020. Integrative medicine for COVID-19: Researches and evidence.|pdf=|usr=018}}
| |
| − | {{tp|p=32834993|t=2020. Clinical practice guidelines for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32834992|t=2020. Chinese medical drugs for coronavirus disease 2019: A systematic review and meta-analysis.|pdf=|usr=018}}
| |
| − | {{tp|p=32817820|t=2020. Tongue features of patients with coronavirus disease 2019: a retrospective cross-sectional study.|pdf=|usr=018}}
| |
| − | {{tp|p=32802744|t=2020. Bibliometric analysis of researches on traditional Chinese medicine for coronavirus disease 2019 (COVID-19).|pdf=|usr=018}}
| |
| − | {{tp|p=32766115|t=2020. Enlightenment from clinical trials on Chinese medicine for coronavirus disease 2019 (COVID-19).|pdf=|usr=018}}
| |
| − | {{tp|p=32766114|t=2020. Home-based traditional Chinese medicine nursing interventions for discharged patients with COVID-19: a rapid review of Chinese guidelines.|pdf=|usr=018}}
| |
| − | {{tp|p=32742920|t=2020. Could herbal medicine (Soshihotang) be a new treatment option for COVID-19?: a narrative review.|pdf=|usr=018}}
| |
| − | {{tp|p=32742919|t=2020. Is the traditional Chinese herb "Artemisia annua" possible to fight against COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32727996|t=2020. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.|pdf=|usr=018}}
| |
| − | {{tp|p=32863364|t=2020. Successful Recovery from COVID-19-associated Acute Respiratory Failure with Polymyxin B-immobilized Fiber Column-direct Hemoperfusion.|pdf=|usr=018}}
| |
| − | {{tp|p=32812114|t=2020. Psychoactive compounds as multifactorial protection factors against COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32801412|t=2020. The Rise and Fall in Therapeutic Candidates for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32818905|t=2020. ACE2, Metformin, and COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32738617|t=2020. ACE2 Co-evolutionary Pattern Suggests Targets for Pharmaceutical Intervention in the COVID-19 Pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32812725|t=2020. Hydroxychloroquine-related Rash in COVID-19 Infected Patient.|pdf=|usr=018}}
| |
| − | {{tp|p=32812720|t=2020. Bacillus Calmette-Guerin (BCG) as a Protective Factor for COVID-19?|pdf=|usr=018}}
| |
| − | {{tp|p=32812718|t=2020. Bacillus Calmette-Guerin vaccination Policy and Consumption of Ammonium Chloride-Enriched Confectioneries May Be Factors Reducing COVID-19 Death Rates in Europe.|pdf=|usr=018}}
| |
| − | {{tp|p=32812340|t=2020. Vitamin B12 may inhibit RNA-dependent-RNA polymerase activity of nsp12 from the SARS-CoV-2 virus.|pdf=|usr=018}}
| |
| − | {{tp|p=32855101|t=2020. Practical Guidance for Dietary Management of Patients With Inflammatory Bowel Disease During the SARS-CoV2 Pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32807723|t=2020. Effects of Probiotics in Conditions or Infections Similar to COVID-19 on Health Outcomes: An Evidence Analysis Center Scoping Review.|pdf=|usr=018}}
| |
| − | {{tp|p=32792328|t=2020. Telehealth and Nutrition Support During the COVID-19 Pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32777318|t=2020. Review of adverse cutaneous reactions of pharmacologic interventions for coronavirus disease 2019 (COVID-19): a guide for the dermatologist.|pdf=|usr=018}}
| |
| − | {{tp|p=32860913|t=2020. Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients - A meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic.|pdf=|usr=018}}
| |
| − | {{tp|p=32766679|t=2020. Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.|pdf=|usr=018}}
| |
| − | {{tp|p=32750131|t=2020. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.|pdf=|usr=018}}
| |
| − | {{tp|p=32812039|t=2020. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.|pdf=|usr=018}}
| |
| − | {{tp|p=32812025|t=2020. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.|pdf=|usr=018}}
| |
| − | {{tp|p=32782662|t=2020. Risk of QTc prolongation with Chloroquine/Hyroxychloroquine and Azithromycin treatment for COVID-19: Quantification and precautions for a busy clinician.|pdf=|usr=018}}
| |
| − | {{tp|p=32843231|t=2020. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32837100|t=2020. An Ayurvedic Perspective along with in Silico Study of the Drugs for the Management of Sars-Cov-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32863675|t=2020. Principles of Rajayakshma management for COVID-19.|pdf=|usr=018}}
| |
| − | {{tp|p=32837101|t=2020. Immunity Against COVID-19: Potential Role of Ayush Kwath.|pdf=|usr=018}}
| |
| − | {{tp|p=32802787|t=2020. Low Dose Radiation Therapy and Convalescent Plasma: How a Hybrid Method May Maximize Benefits for COVID-19 Patients.|pdf=|usr=018}}
| |
| − | {{tp|p=32741313|t=2020. Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2.|pdf=|usr=018}}
| |
| − | {{tp|p=32713863|t=2020. Computational search for potential COVID-19 drugs from FDAapproved drugs and small molecules of natural origin identifies several anti-virals and plant products.|pdf=|usr=018}}
| |
| − | {{tp|p=32877501|t=2020. Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function.|pdf=|usr=018}}
| |
